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To my father 
 
 
 
 
 
     “The most important thing that parents can teach their children is how 
to get along without them.” 
 
Frank A. Clark 

  
ABSTRACT 
 
Cancer still represents one of the leading causes of death despite the advances achieved during the 
past years. Improving the outcome of cancer patients requires the identification of more affective 
therapeutic strategies and a better understanding of the molecular mechanisms involved in the 
progression of the disease. Recently, the tumor metabolic reprogramming has been included in the 
hallmarks of cancer and one features associated with tumor metabolism is acidosis, which represents 
an environmental pressure contributing to the selection of malignant cells. For its contribution to 
tumor progression and therapy-resistance, the acidic tumor environment is being investigated as a 
target for cancer therapy. 
In this study, we have characterized the catabolic autophagic process as a fundamental survival 
mechanism acting in cancer cells exposed to acidic conditions in order to adapt to the harsh 
environment. This finding, coupled to the role of autophagy in drug-resistance, suggests the use of 
autophagy inhibitors in cancer treatment as a strategy to better target malignant cells localized in a 
metabolically stressed environment and considered responsible for tumor progression, invasion, 
chemoresistance and disease relapse. We have observed that the autophagy inhibitor Chloroquine used 
in clinical studies is not the optimal drug for this purpose since it fails to inhibit the autophagic process 
and to induce toxicity on cancer cells in acidic conditions. Therefore, we aimed at identifying more 
effective compounds also active in conditions of acidosis. Salinomycin, also known to specifically kill 
cancer stem cells showed a preferential cytotoxic activity in cells under acidosis, a phenomenon 
associated with its ability to inhibit autophagy also at low pH. Finally, we developed a model of drug 
screening performed on cancer cells chronically adapted to pH 6.8 in order to identify compounds 
targeting cells in metabolic stress conditions. We identified Verteporfin as a promising new anticancer 
drug able to target colon carcinoma cells adapted to low pH better than cells in physiological 
conditions through a mechanism that still need to be further investigated. 
We can conclude that a better understanding of the cellular mechanisms involved in the cell adaptation 
to tumor acidosis is important for the identification of new therapeutic targets and selective anticancer 
drugs overcoming acidosis-mediated drug-resistance. 
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1 INTRODUCTION 
 
1.1    CANCER 
Cancer is one of the leading causes of death in the world. According to the most recent World Health 
Organization report, 8.2 million people die for cancer every year, the 13% among all deaths, and the 
incidence of new cases is expected to increase by about 70% in the next years. Over the past years, 
significant progresses have been made in the field of cancer prevention, diagnosis and therapy but 
there is a major need to improve the outcome of cancer patients. A better understanding of the tumor 
biology combined with the development of new, specific and effective therapeutic strategies are 
fundamental to achieve better results. 
Cancer is a spread multifactorial disease characterized by high heterogeneity. However, cancer cells 
share several hallmarks that make them different from normal cells. In 2000, Weinberg and Hanahan 
first described enabling replicative immortality, evasion of cell death and growth suppression, 
activating proliferation, invasion and angiogenesis as the six main principles driving the 
transformation process from a normal to a malignant cell 1. Cancer cells develop from functional 
normal tissues and they give origin to malfunctioning and disorganised new tissues that interfere and 
impair the function of organs in which they arise. Tumors can be classified according to site of origin. 
The most common type of tumors arise from epithelial cells and they are named carcinoma while 
sarcomas, blood cells tumors and nervous system tumors develop from mesenchymal, hematopoietic 
and neuroectodermal tissues, respectively 2. Tumors are defined as benign when they are non-invasive 
and localized in a determined area, however they become malignant once they acquire the ability to 
invade different organs and metastasize 3. Metastasis is a peculiar characteristic of malignant tumors 
and it consists in the seeding of tumor colonies in distant sites of the body. The multistep process - 
local invasion, intravasion, blood circulation, extravasion and colonization - is mediated by metastatic 
cancer cells acquiring malignant features like adaptation to environmental changes, motility and 
invasiveness 4,5.  
About the 90-95% of tumors are correlated to environmental issues while only the 5-10% are due to 
hereditary factors 6. Different genetic mutations are closely linked to specific types of cancer: 
alterations in breast cancer susceptibility genes 1/2 (BRCA1/2) are associated to breast and ovarian 
cancer 7, c-Myc modifications cause Burkitt lymphoma 8, mutation in the gene for the retinoblastoma 
protein (Rb) is responsible for retinoblastoma 9 and p53 mutations cause the Li-Fraumeni syndrome 10. 
However, every type of cancer is characterized by many different alterations that are direct 
consequence of environmental factors. Among these factors, lifestyle, chemical and physical agents, 
infections and radiations have been the most studied and described 11,12,13. Diets rich in fats and 
proteins are correlated to the production of carcinogens but on the other hand a proper intake of fruit 
and vegetables as well as a correct physical activity seem to have a preventive effect on cancer 
development 14,15. In obese people activation of the insulin/IGF-1/Akt pathway leads to inflammatory 
processes correlated to cancer onset 16. In 1915, Yamagiwa treated rabbits with coal tar, a known 
chemical carcinogen which induced skin carcinoma in the animal ears. Since then, many molecules 
have been classified as mutagenic and/or tumorigenic: biocides and pesticides, dioxine and 
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oganochlorines, metals and asbestos have been shown to induce cancer through their ability to induce 
genetic mutations 17. Infections are considered one of the major causes of cancer. For instance, 
Helicobacter pylori infection can cause stomach cancer, Hepatitis B and C viruses lead eventually to 
liver cancer, Epstein-Barr virus is associated to Burkitt’s lymphoma and human papillomavirus is 
correlated to cervix uterine cancer 12,18. The mechanisms involved are still under investigation but 
chronic inflammation seems to drive the tumorigenic process, after viral infection, through the 
inflammatory marker nuclear factor kappa B (NF-kB) 19-21. Finally, a clear correlation between 
radiation and cancer has been described already long time ago since physicians and health personnel 
working with X-rays are subjected to higher risk of developing cancers 22,23. X-ray, gamma rays and 
UV are carcinogenic and lead to several type of tumors such as leukemia, lymphoma, thyroid cancers, 
skin cancers, sarcomas, lung and breast carcinomas 6.  
 
1.2    CANCER TREATMENT 
The field of cancer treatment has made great progresses during the last decades. In fact, until 70 years 
ago surgery was the only approach used in cancer therapy. Since then, other methodologies have been 
developed and improved such as radiation therapy, chemotherapy, targeted therapy, hormone therapy 
and immunotherapy 24. The surgical removal is still the first line approach that is considered in cancer 
patients with a solid tumor as long as the localization and the grade are advantageous 25. However, in 
most cases surgical intervention is not sufficient due to technical limitations and to the aggressive 
nature of the tumor. In fact, cells that are not removed keep growing and spreading in surrounding 
tissues. For this reasons, surgery is often combined with other forms of treatment 26. 
Radiation therapy exploits the ability of ionizing radiation to provoke DNA damages that cancer cells 
are often not able to repair due to alterations in their DNA repair systems 27,28. Normal cells 
surrounding the tumor are also affected by radiations but they hold functional repairing system to cope 
with the damage 29. Radiotherapy is combined with chemotherapy for a better outcome but different 
results are obtained depending on different type of tumors 30. For instance, melanoma cells are really 
resistant to high doses of radiation while low doses are sufficient to successfully target other types of 
tumors such as leukemia 31,32.  
Chemotherapy is the mainstream therapeutic approach used in cancer patients. In 1940, the first 
chemotherapeutic drug, a nitrogen mustard was used to treat lymphomas 33. Since then many other 
molecules have been developed, characterized, approved and used for treatment of cancer patients. 
Most of the drugs belong to a specific class depending on molecular structure and mechanism of 
action: alkylating agents, antimetabolites, topoisomerase inhibitors, antibiotics, anti-microtubule 
agents and hormones.  In general, chemotherapeutic agents induce DNA damage and impairment in 
the cell cycle, which lead to cell death through apoptotic pathway 34,35. 
 
Alkylating agents mainly inhibit DNA replication but also alter RNA transcription and protein 
synthesis. The mechanism of action is based on their ability to insert alkyl groups (CnH2n+1) in 
nucleobases, especially in position N7 of guanine 36. The consequences are cross-links within the 
double strand helix followed by inhibition of the DNA replication. Alkylating drugs are not phase-
  
3 
specific and they affect cancer cell DNA but also normal proliferating cells, like hematopoietic cells, 
resulting in high toxicity. There are different classes of alkylating agents 37: 
 
• Nitrogen mustards include mechlorethamine, cyclophosphamide, ifosfamide, busulfan, and 
melphalan. 
• Nitrosoureas include carmustine, lomustine, fotemustine, semustina, and N-nitroso-N-
methylurea. 
• Tetrazines include temozolomide, mitozolomide and decarbazine. 
• Aziridines include mytomycin and thiotepa. 
• Platinum drugs include cisplatin, oxaliplatin and carboplatin. 
• Non-classical alkylating agents include procarbazine. 
 
Antimetabolites are chemical analogues of nucleotides constituents that are necessary for the synthesis 
of DNA and RNA. They can either interfere with the formation of the pyrimidine and purines rings or 
directly substitute the biological molecules. They differ from alkylating agents for their specific 
inhibitory activity of the S-phase of the cell cycle: they block DNA synthesis and so mitosis, leading 
the cell to apoptosis 38. There are different classes of antimetabolites: 
 
• Purines analogues are thioguanine and mercaptopurine. 
• Pyrimidine analogues are 5-fluoroacil, capecitabine and 5-bromouridin. 
• Anti-folates are methotrexate and pemetrexed. 
 
Topoisomerase inhibitors interfere with the function of important enzymes involved in many 
processes of DNA transcription, replication and recombination. In fact, these enzymes are involved in 
the unwinding of the double strand DNA that as single strand can enter mitosis and continue the cell 
cycle. The inhibition of these enzymes leads to apoptosis 39. There are two classes of topoisomerase 
inhibitors: 
 
• Topoisomerase I inhibitors include camptothecin, topotecan and irinotecan. 
• Topoisomerase II inhibitors include, mitoxantrone, novobicin and etoposide. 
 
Antibiotics are used in cancer therapy as cytotoxic drug due to their ability to intercalate the DNA. 
They form covalent bonds with nucleic acids interfering with DNA replication and synthesis and 
inhibiting progression of the cell cycle. Moreover, some antibiotics lead to the production of reactive 
species that induce DNA damage 40. 
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• Antibiotics used are puromycin anthracyclines, doxorubicin, daunorubicin, actinomycin, 
epirubicin and plicamycin. 
 
Anti-microtubule agents often derive from natural products and they interfere with the microtubule 
function resulting in blocking of cell division. In fact, microtubules are fundamental for mitotic 
process and the inhibition of their assembly or disassembly cause the block of the cell cycle and 
apoptosis 41,42. Two main groups of anti-microtubule agents can be distinguish: 
 
• Vinca alkaloids include vinblastine and vincristine. 
• Taxanes include paclitaxel and docetaxel. 
 
Targeted therapy affects cancer cell growth by targeting specific molecules that are overexpressed 
and/or hyperactive in tumor cells. Most of the conventional chemotherapeutic drugs have low 
specificity, resulting in high toxicity and reduced efficacy but new biomedical technologies have led to 
the development of more specific strategies 43-45. For instance, cancer cells synthetize and expose on 
the plasma membrane specific antigens that are normally recognized by the immune system and 
specific monoclonal antibodies for particular antigens are used in order to activate immune cells 
against the tumor 32. Moreover, small molecules have been identified as specific and effective 
inhibitors of certain proteins overexpressed in tumor cells, such as growth factor receptors or protein 
kinases 46,47. 
 
• Some examples of targeted cancer therapy agents are erlotinib and imatinib targeting tyrosine 
kinases, bortezomib targeting the proteasome and cetuximab, targeting the epidermal growth 
factor receptor (EGFR) 48-51. 
 
1.3    CANCER RESISTANCE 
The major limitation in cancer therapy is chemoresistence. Chemotherapy represents the most 
common treatment for cancer patients but in many cases malignant cells do no respond to drugs and/or 
develop resistance 52. In particular, slow proliferating and quiescent cancer cells are not ideal targets of 
chemotherapeutics since these drugs usually target proliferating cells by affecting DNA replication 53. 
Moreover, metastatic cells are genetically instable and heterogeneous due to multiple mutations 
acquired over time resulting in survival of chemoresistant subpopulations. Two types of drug 
resistance can be distinguished, a primary (or intrinsic) and an acquired drug-resistance which can be 
correlated to treatment failure and disease relapses, respectively 54. Primary resistance is correlated to 
intrinsic features that make cancer cells insensitive to the treatment 53. Several mechanisms have been 
studied and considered responsible such as mutations or expression of proteins that prevent drug 
activity. The resistance that arises after one or more complete cycles of chemotherapy is defined as 
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acquired and the mechanisms involved are a consequence of an adaptive response to drugs; for 
instance, mutations affecting the apoptotic pathway are considered responsible for acquired resistance 
as well as altered expression of ATP-binding cassette (ABC) transporters 55,56. Drug-resistance is 
mediated by both cellular events and the complex tumor physiology 57. At cellular level the following 
mechanisms have been described: reduction of drug uptake and increase of drug efflux, alteration of 
apoptotic pathways, mutations/alterations of the drug targets, enhanced DNA repair and upregulation 
of autophagy. However, hypoxia, altered perfusion, reduced drug diffusion as well as the high 
interstitial fluid pressure (IFP) are more correlated to the most general anatomy and physiology of the 
tumor 57. 
 
Ion trapping 
The ion trapping is a mechanism through which anions accumulate in a particular cell compartment 
depending on their charge and the pH gradient across the compartment membrane. Normally, weak 
acids and weak bases ionize differently, depending on the pH of the solution, in the charged species 
that exist in equilibrium with the uncharged form. For instance, basic drugs that enter cells and cross 
the lysosomal membrane become protonated due to the acidic lysosomal pH. The positive charged 
molecules are not able to cross back the membrane and they are trapped in the organelles preventing 
them to reach their molecular target 58. 
 
Drug transport 
Hydrophobic and small molecules can easily cross the plasma membrane by diffusion but charged and 
big compounds need transporters to enter the cells. Mutations of these transporters lead to reduction of 
the drug uptake, as in the case of methotrexate resistance 59,60. Moreover, cancer cells overexpress 
membrane transporters whose biological role is to extrude toxins and xenobiotics outside cells. 
Among these, P-glycoprotein (P-gp) and multi drug resistance-associated protein 1 (MRP-1), 
belonging to ABC transporters 61,62, control the transport of many chemotherapeutic agents 52,63 and 
their overexpression is responsible for multidrug resistance (MDR), a phenomenon consisting in the 
cross-resistance to several drugs with different properties and mechanisms of action 64.  
 
Mutations 
Cancer cells undergo many mutations which may confer the resistant phenotype. Mutations in 
apoptotic pathway can prevent cancer cell death induced by a proapoptotic stimulus. In particular, 
reduced expression of proapoptotic proteins such as Bax and p53 and increased activity of 
antiapoptotic proteins like B cell lymphoma 2 (Bcl-2) impair the ability of the cells to undergo 
programmed cell death 65.  Malignant cells exposed to targeted therapy can also mutate the specific 
drug targets, thus evading the cytotoxic effects 66,67. Moreover, mutations responsible for 
overexpression of genes involved in DNA repair make cancer cells able to overcome chemotherapy-
mediated mutations, thus enabling cancer cells to escape from apoptosis 68. 
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Tumor structure and physiology 
Outgrowth of high proliferating tumor cells lead to the development of an abnormal or absent 
vascularization within the tumor mass. A direct consequence is a defective perfusion resulting in a 
lower delivery of nutrients and oxygen but also of drugs. Therefore, therapeutic compounds are not 
able to reach at the tumor site the cytotoxic doses necessary to kill cells 69. This is also correlated to 
the localization of some tumors in areas which are difficult to reach, such as the central nervous 
system, due to the high selective permeability of the blood-brain barrier (BBB) 70,71. Moreover, some 
of the chemotherapic agents induce cytotoxicity through reactions that produce reactive oxygen 
species and cancer cells located in area with oxygen shortage are resistant to such compounds 33 72. 
Chemoresistant cancer cells are considered a major determinant of tumor relapses that in most cases 
will lead to death of the patient. Due to the onset of mutations, cancer cells easily develop resistance 
mechanisms even against the most promising targeted therapies 69. For these reasons, therapeutic 
strategies need to be developed and/or improved in order to overcome limits of conventional therapies. 
Cancer is considered a multifactorial disease after all and more than one type of treatment is necessary 
to deal with it. During the last decades, the scientific community has accepted the idea of the tumor as 
a complex system characterized not only by cancer cells but also by the surrounding and supporting 
milieu. Therefore, new studies are aimed at developing drugs able to target the tumor 
microenvironment in order to more efficiently kill cancer cells and possibly prevent and/or overcome 
chemoresistance.  
 
1.4    TUMOR MICROENVIRONMENT 
The tumor microenvironment of solid tumors is a complex and heterogeneous system characterized by 
different type of cells, cells of the tumor microenvironment, such as cancer cells, cancer stem cells, 
endothelial cells, fibroblasts and immune cells 73,74. Moreover, several physical and biochemical 
factors such as metabolites, protons, oxygen and nutrients contribute to characterize the tumor 
microenvironment 75. In particular, the high proliferative tumor mass growing far from blood vessels 
is characterized by low perfusion and poor vascularization, correlated to a decrease in nutrients and O2 
delivery and accumulation of metabolic acids leading to tumor hypoxia, tumor acidosis and 
nutrient deprivation, important features that affect tumor metabolism 76-78. 
 
1.4.1   CELLS OF THE TUMOR MICROENVIRONMENT 
Cancer cells and cancer stem cells (CSCs) 
Cancer cells represent the main cellular population of the tumor mass. Different and heterogeneous 
populations of malignant cells are distinguished and localized in different area of the tumor. They 
mainly differ for the differentiation status, the genetic profile and for the metabolic profile (discussed 
in the next paragraphs), preferring a more glycolytic or oxidative metabolism. The multiregional 
genetic analysis of samples derived from tumor biopsies has revealed a large intratumor heterogeneity 
characterized by a regional distribution of mutations. In particular, about 70% of all somatic mutations 
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observed in the sequencing analysis were heterogeneous and not detected in every tumor region 
analyzed 79. 
More recently, CSCs have been described as a new, although small, sub-population of cancer cells. 
They were isolated from different types of hematopoietic tumors first 80,81 and later also in solid 
cancers, like breast, prostate, colon, brain, and pancreatic cancers 82-86. CSCs differ from other cancer 
cells due to the expression of stemness markers 83. They are functionally defined by their strong ability 
to promote tumor formation in immunocompromised mice and they are characterized by self-renewal 
ability and capacity to differentiate into non-stem cancer cells forming the tumor. The mechanisms 
involved in CSCs origin are still unclear and they might depend on the type of tumor. However, the 
gaining of CSCs features might be the consequence of epithelial to mesenchymal transition (EMT) or 
mutations of oncogenes and/or tumor suppressor genes in normal adult stem cell. In particular, EMT-
inducing factors (EIFs) could induce EMT transforming epithelial cells in to mesenchymal, fibroblast-
like cells that in turn become CSC as a result of mutations 87,88. The possible connection with the 
EMT, which is a reversible program 89, may indicate that the switch between CSCs and non-CSCs 
could be also reversible and dynamic 90. Due to their strong ability to differentiate and their low 
proliferating rate, chemotherapy often fails to target CSCs which are considered responsible for 
metastasis, chemoresistence, tumor relapse and poor prognosis 91.  For instance overexpression of 
CSCs markers such as CD133, CD24, CD34 and CD44 have been correlated to resistance to 
conventional drugs and poor prognosis in some types of tumors 92,93. 
Stromal cells – Pericytes, Cancer-Associated Fibroblasts (CAFs), Endothelial cells and immune cells 
Pericytes are mesenchymal cells which support the endothelium of blood vessels. They have a 
paracrine function since they regulate homeostasis of endothelial cells by secreting molecules such as 
Ang-1 and vascular endothelial growth factor (VEGF) 94,95. It has been shown that pericytes have 
important role in supporting the tumor endothelium during the formation of new blood vessels through 
the platelet-derived growth factor (PDGF) signaling. In fact, the specific inhibition of the PDGF 
receptor alters and disrupts blood vessels responsible for cancer cells growth, proliferation and 
dissemination 74,95. 
Fibroblasts belong to the connective tissue and structurally support epithelial cells. In case of chronic 
inflammation, such as in cancer, myofibroblasts predominate on normal tissue-derived fibroblasts 
causing pathological fibrosis. Myofibroblasts produce and release the α-smooth muscle actin (SMA), 
and promote cancer cell proliferation, angiogenesis, invasion and metastasis 74,96. Tumor stromal cells 
differentiate from progenitor cells existing in the normal tissue surrounding the tumor or from stem 
cells deriving from the bone marrow 97. 
Endothelial cells are fundamental constituent of blood and lymphatic vessels. The formation of the 
new tumor vasculature is associated to the development and differentiation of new endothelial cells. 
Several pathways are involved in tumor-associated angiogenesis such as VEGF and fibroblast growth 
factor (FGF) signals 98. It has been shown that endothelial cell associated to tumor express different 
markers as compared to normal endothelia 99. 
The immune system plays an important role in tumor development and tumor progression. In 
particular, it displays a double activity in cancer due to the fact that it is involved in processes which 
 8 
can inhibit but also promote tumor growth and progression. Several different types of infiltrating 
immune cells have been observed in tumors: macrophages, T and B-lymphocytes, neutrophils, mast 
cells and NK cells 100. During transformation from a normal cell toward a malignant phenotype, 
immune cells like NK cells and cytotoxic T lymphocytes intervene in order to eliminate transformed 
cells. However, in many cases the chronic inflammatory status characterizing the tumor tissue 
eventually triggers biological processes promoting tumor progression, like angiogenesis and fibrosis 
101,102.  
The interaction between cancer and stromal cells is complex and dynamic, they communicate 
continuously through signaling molecules that are released from both type of cells 74. It has been 
suggested that cancer cells actively recruit the stromal cells that are fundamental to support tumor 
growth and progression. Stromal cells, in turn are able to provide signals back to cancer cells which 
enhance the malignant phenotype until they can invade different tissue and metastasize. Therefore, 
metastasizing cells, arrived at the new site, start again the cell interactions with the local stroma in 
order to settle in the new organ 103. 
 
1.4.2   TUMOR METABOLISM 
In 2011, Weinberg and Hanahan revised their theories on hallmarks of cancer (previously described) 
and added four more features characterizing cancer cells. Among these, the cancer cell capability to 
regulate the energy metabolism is nowadays raising a lot of interest, especially about the possibility of 
developing new therapeutic targets 104.  
Adenosine triphosphate (ATP) is the energy source for cells and it is essential for the functioning of all 
cellular processes. In normal conditions, at physiological levels of oxygen, cells rely on oxidative 
phosphorylation as main source of ATP, with a yield of 38 molecules of ATP per molecule of glucose 
oxidized. First, glucose is oxidized into pyruvate that translocate into the mitochondria and it is 
transformed in acetyl-CoA. Acetyl-CoA enters the Krebs cycle and its oxidation leads to reduction of 
the redox cofactors NAD+ and FADH into NADH and FADH2, respectively. These two reduced 
cofactors are further oxidised in mitochondria in the electron transfer respiratory chain leading to the 
production of ATP through the activity of the ATP synthase. In conditions of low oxygen levels, 
oxidative phosphorylation cannot be accomplished and cells produce ATP only through the glycolytic 
pathway, defined as anaerobic glycolysis. Hypoxia triggers the stabilization and upregulation of the 
hypoxia-inducible factor 1 α (HIF1α), a transcription factor which upregulates the transcription of 
more than 60 genes regulating angiogenesis, apoptosis and metabolism 105,106. In fact, HIF1 α is 
involved in the transcriptional activation of proteins involved in biological processes aiming at 
increasing oxygen supply to tissues, such as the VEGF, a cytokine promoting angiogenesis 107, the 
insulin-like growth factor-2 (IGF2) and transforming growth factor-α (TGF-α), correlated to cell 
proliferation and survival 108,109. Moreover, HIF1 α regulates genes involved in glycolysis which is the 
pathway on which cells rely on in case on lack of oxygen: glucose transporters like GLUT1 and 
GLUT3 are upregulated as well as several enzymes involved in the glycolysis, such as hexokinase 
(HK-II) and 6-phosphofructo-2-kinase (PFK-2) 110-114. 
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Otto Warburg was the first one describing a deregulated cancer energy metabolism in 1924 115. 
Malignant cells as well as highly proliferative cells switch their metabolism from the more efficient 
(in term of ATP production) oxidative phosphorylation to glycolysis, even in presence of a 
physiological oxygen pressure (Warburg effect), resulting in aerobic glycolysis. Cancer cells 
counterbalance the lower yield of ATP by upregulation of glucose uptake and by increasing the 
glycolytic rate. In fact, overexpression of glucose transporters and glycolytic enzymes has been 
correlated to malignant cells 116. This feature of cancer cells has been successfully used for diagnostic 
purposes since radiolabeled glucose analogue 18F-fluorodeoxyglucose (FDG) has been exploited in 
positron emission tomography (PET) to detect tumor lesions characterized by an increased avidity for 
glucose 117.  
Mechanisms involved in the metabolic switch have been investigated and mutations in oncogenes and 
tumor suppressor gens are correlated to reprogramming of cell metabolism (Fig. 1) 110,118,119. For 
instance, the tumor suppressor transcription factor p-53 has been found mutated in more than 50% of 
cancers and its alteration is correlated to upregulation of glucose transporters and down regulation of 
TP53-induced glycolysis and apoptosis regulator (TIGAR), which lead to an increased glucose uptake 
and increased glycolysis through regulation of fructose-2,6-bisphosphate (F2,6BP) levels, respectively 
119-121. C-Myc is an oncogene which is correlated to increased glucose uptake and glycolysis, 
glutamine uptake and metabolism as well as biogenesis of mitochondria 119,122-124.  
 
 
Figure 1.  Oncogenes and tumor suppressors directly control cell metabolism. Various signalling pathways 
and genes regulate different metabolic pathways. Glycolysis, oxidative phosphorylation, pentose phosphate 
pathway and glutamine metabolism are interconnected and controlled by signalling pathways that are commonly 
altered in cancer (Figure by Vander Heiden et al. 2009) 118.  
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Molecular mechanisms involved in the metabolic reprogramming have been well described and 
potential explanations of the phenomena have been provided. For several years it has been unclear 
why cancer cells that have a great need of ATP would switch from a high productive energetic 
pathway, the oxidative phosphorylation, to glycolysis, faster but less efficient. In 2009, Vander 
Heiden provided a reasonable explanation claiming the metabolic switch as an advantage for cancer 
cells to quickly synthetize new cellular components. Highly proliferative cells, like cancer cells, 
constantly need to generate new nucleic acids, proteins and membranes for the new forming cells. 
Oxidative phosphorylation produces more ATP molecules that are eventually employed in to 
biosynthetic anabolic pathways but the whole process takes long time and it is not compatible with the 
needs of high proliferative cells. Conversely, increased glycolysis produces low amount of ATP but 
glycolytic intermediates and reducing agents (through the oxidative pentose phosphate pathway) can 
be fast and directly recycled for macromolecules biosynthesis 117,118,125.  The scientific community has 
agreed on considering the metabolic reprogramming as a adaptive mechanism to the dynamic stressful 
tumor environment126. 
Finally, tumors are really heterogeneous systems characterized by cells with different phenotype that 
coexist and cooperate for a better chance to survive. Different models of cooperating cells have been 
described. Sonveaux and colleagues described a cooperative model between oxidative and glycolytic 
tumor cells. According to this model glycolytic tumor cells metabolize glucose producing and 
releasing lactate, which is taken up by oxidative tumor cells and enters the TCA cycle after conversion 
to pyruvate 127,128. Lisanti and colleagues suggested a reverse Warburg effect in which lactate acts as a 
mediator. In fact, they showed that high glycolytic cancer CAFs of the tumor stroma produce lactate 
that in turn is used by oxidative tumor cells. In both cases, the glycolytic-dependent cells and lactate-
dependent cells work symbiotically achieving a more malignant phenotype. In fact, lactate production 
is not anymore considered as a collateral and toxic by-product of an augmented glycolysis but rather 
as a metabolic fuel and signaling molecule fundamental for tumor growth and progression. High 
levels of lactate have been associated to metastasis, chemoresistance, recurrence and poor clinical 
outcome in different human cancers 129,130. 
 
1.4.3   TUMOR ACIDOSIS 
The reprogramming of tumor metabolism has been associated with tumor acidosis and the upregulated 
glycolysis is considered to contribute to acidification of the extracellular tumor microenvironment 
along with other correlated molecular mechanisms 131. During glycolysis one molecule of glucose is 
oxidized to two molecules of pyruvate and two protons (H+). In normal cells pyruvate enters in the 
mitochondria and undergoes the TCA cycle while in cancer and high proliferative cells pyruvate is 
reduced to lactate by lactate dehydrogenase (LDH). Moreover, most human metabolic pathways end 
with production of CO2 that is hydrated with water by carbonic anidrases (CA) and transformed in 
carbonic acid, one molecule of HCO3- and one H+, thereby contributing to protons production. In 
normal cells, intracellular pH is equal to 7.2, slightly more acidic than the physiological extracellular 
pH 7.4. However, in cancer cells, high metabolic rates and protons accumulation may lead to a further 
acidification which negatively affects enzymatic activities and protein structures. In order to cope with 
the toxic cytosolic acidification and maintain the proper intracellular pH, tumor cells activate transport 
systems that lead to alkalinisation of cytosolic pH and to acidification of the extracellular pH. There 
  
11 
are several proteins contributing to pH buffering (Fig. 2). The monocarboxylate transporters (MCT) 
intervene in the co-transport of one H+ and one monocarboxylate such as lactate across the plasma 
membrane 132; the Na+/H+ exchangers is a transmembrane sodium-hydrogen antiporter that becomes 
active during cytosolic acidification in order to extrude one proton for each sodium that is taken up, 
contributing to extracellular acidification 133; the vacuolar-ATPase is a transmembrane proton ATPase 
localized on endo-lysosomal and plasma membranes involved the intraluminal and extracellular 
acidification through protons translocation 134; CA are metalloenzymes able to reversibly catalyze the 
hydration of carbon dioxide into bicarbonate and protons, thereby regulating both intracellular and 
extracellular pH 135. The upregulation of these proteins by cancer cells along with a disorganized 
vasculature and inefficient perfusion and clearance is responsible for acidification of extracellular pH 
136. Indeed, cancer cells show a reversed plasma membrane pH gradient since the intracellular pH is 
slightly more alkaline (from 7.2 up to 7.7) while the extracellular pH is acidic (as low as 6.0) 131.  
 
 
Figure 2. Regulation of pH homeostasis in tumor cells. The main players involved in pH regulation in tumor 
are: monocarboxylate transporters (MCTs), Na+/H+ exchangers (NHEs), the plasma membrane proton pump 
vacuolar ATPase (V-ATPase), Na+/HCO3– co-transporters (NBCs) and carbonic anhydrase 9 (CA9). Tumor cells 
present a reversed pH gradient, with a pHi slightly alkaline and a pHe slightly acid (Figure by Angelo De Milito). 
 
Tumor acidosis is not just the final result of tumor metabolism reprogramming but it is important for 
cancer cells to acquire selective advantages necessary for the achievement of a more aggressive 
phenotype 137,138. In fact, the toxic environment can enhance invasiveness, chemoresistence, 
mutagenesis and neo-angiogenesis in those malignant cells located in hypoxic and acidic areas of the 
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tumor mass, leading to a selective advantage facilitating escape from apoptosis, unlike normal cells 
(Fig. 3) 128.  In fact, it has been showed that acidic extracellular pH induces the secretion of proteases, 
such as cathepsins and matrix metalloproteinases (MMP) which drive the degradation of the ECM. 
The disruption and remodeling of the matrix facilitates the migratory and invasive behavior of cancer 
cells toward a metastatic and more aggressive phenotype 139.  
 
 
 
Figure 3.  The altered tumor pH is correlated to malignant features. (Figure by Strambi and De Milito, 
2015) 
 
This ability is further enhanced by acidosis-induced release of proangiogenic factors, such as VEGF 
and IL-8, which trigger the formation of new blood vessel used by cancer cells to spread to new 
different sites 140,141. Acidosis is also correlated to a reduced capability of DNA repair leading to a 
further increase of genomic mutations 142. Acidic extracellular pH has been also correlated to 
inhibition of expression of several inflammatory markers and induction of anergy in T cells, thereby 
inactivating the immune system and promoting immune escape 143,144. Moreover, acidosis has been 
described as one important factor that induces chemoresistance for the “ion trapping” phenomenon 
and upregulation of p-glycoprotein, as previously described 145,146. Eventually, tissue acidosis also 
modulates autophagy as a survival and adaptive mechanism  (this part will be better discussed in this 
thesis) 147-149.  
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Resistance to chemotherapy is one of the several benefits acquired by malignant cells during acidosis 
and it leads to treatment failure and relapse. In fact, one factor modulating drug efficacy is the ability 
of compounds to cross the plasma membrane, which, in turn, is correlated to the chemical properties 
of molecules and to interstitial/intracellular pH gradients 36. Small and uncharged molecules can easily 
pass through the lipid bilayer of biological membranes. However, many conventional anticancer drugs 
are weak bases and weak acids, protons acceptors and proton donors respectively, which exist as 
equilibrium of the uncharged and the protonated charged forms 150. This implies that weak bases 
accumulate in acidic compartments while weak acids concentrate in alkaline compartment for the “ion 
trapping”, responsible for chemoresistance in acidic tumors 58,145,151. As we have previously described, 
solid tumors are characterized by a reversed pH gradient with a more acidic extracellular pH and 
slightly more alkaline intracellular pH as compared to normal cells 152.  In this condition, weak bases 
(such as doxorubicin), in their ionized form, cannot easily enter the cells and perform their cytotoxic 
activity while weak acids (such as 5-FU), in their neutralized form, easily enter the cells 145. Tumor 
acidosis has been considered a new therapeutic target in cancer therapy and several drugs may target 
pathways involved in the regulation of the tumor pH. Targeting and inhibiting buffering systems have 
shown promising results in preclinical studies showing the ability of such drugs to alter pH 
homeostasis in the tumor mass and to induce apoptosis. Proton pump inhibitors (PPIs), such as 
omeprazole and esomeprazole, are pro-drugs activated only in acidic conditions and already used in 
clinic for the treatment of peptic diseases due to the fact that they inhibit the gastric proton-ATPase 153. 
Moreover, PPIs have been associated to reverse the chemoresistence of several conventional 
chemotherapeutic drugs. In fact, the pre-treatment of human tumor xenografts with PPIs led to 
alkalinization of the tumor microenvironment and increased the sensitivity of cells to treatment with 
cisplatin, 5-FU and vinblastine 151,154. Furthermore, PPIs showed tumor growth inhibition of human 
melanoma and human B lymphoma in xenograft mice model 155,156. These promising results 
represented the proof of principle that PPI can be used as anticancer drugs and the preclinical studied 
opened the possibility to introduce these drugs in clinic on breast cancer patients 157. The 
sulphonamide Indisulam (E7070) showed a potent anticancer activity through the CA inhibition 
inducing cell cycle arrest in vitro and tumor suppression in vivo 158-160. During the past years several 
classes of CA inhibitors (CAIs) with different mechanism of action have been described and some 
enter the phase I/II of clinical trials for the treatment of metastatic solid tumors 161. Finally, oral 
sodium bicarbonate treatment in mice carrying metastatic breast cancer showed the reduction of 
metastasis formation as a consequence of pH alkalization and it has been considered a promising 
system to overcome the chemoresistance characterizing weak bases through the buffering of tumor pH 
162. 
The acidic tumor microenvironment is a feature of solid tumors that provide a selective pressure to 
cancer cells. Only cancer cells able to adapt, through the several mechanism previously described, can 
acquire a selective advantage becoming more resistant to stress conditions and by aiming at 
invasiveness and metastasis 126. Therefore, targeting tumor acidosis aiming at the restoration of more 
physiological pH leads to alteration of tumor cell homeostasis and to loss of fundamental survival 
mechanisms, resulting in cell death 137.  However there is a great need to identify and better 
characterize survival mechanisms involved during adaptation to acidosis in order to identify new 
potential therapeutic targets and to discover new anticancer compounds selectively active under acidic 
conditions. 
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1.5   CELLULAR DEGRADATION SYSTEMS 
Cells are dynamic systems constantly renewing membranes and cytosolic components through the 
recycle of existing molecules. The turnover of macromolecules, necessary for new biosynthesis and to 
avoid accumulation of damaged/aberrant macromolecules, is mostly driven by two degradation 
systems: autophagy, which is a lysosomal degradation pathway and the ubiquitin proteasome system 
(UPS) which relies on protein degradation through the proteasome 163. Degradation systems are 
important for cellular homeostasis in physiological and pathological conditions and impairment of 
such pathways may lead to cell death. For these reasons, autophagy and the UPS represent new targets 
for therapies in different pathological conditions, including cancer 164,165. 
 
1.5.1   AUTOPHAGY 
The word autophagy is the combination of two Greek words, auto and phagein which combined mean 
self-eating and it refers to the highly conserved and regulated catabolic process that cells use for the 
recycle of cellular components 166. Christian De Duve first discovered and described lysosomes in 
1955 as granules containing acid phosphatase and in 1963 he coined the name “Autophagy” 167. 
Moreover, Ashford and Porter observed autophagic process already more than 50 years ago with 
electronic microscopy. In fact, they localized cytoplasmic components, such as endoplasmic reticulum 
and damaged mitochondria, in lysosomes from rats hepatic cells after exposure to glucagon 12. Since 
then, 3 different types of autophagy have been mainly characterized: microautophagy, 
macroautophagy and chaperone-mediated autophagy (CMA), that mainly differ for the level of 
complexity regarding the delivery process of the cargo to lysosomes 168. Microautophagy is the 
simplest non-selective type of autophagy and it is characterized by a straight invagination of the 
lysosomal membrane intended to engulf directly the cytoplasmic cargo into lysosomes 169. 
Macroautophagy (referred from now on as autophagy) is the most studied pathway and alterations in 
autophagy are associated with a series of human diseases, and in particular with tumor biology. 
Autophagy is characterized by membranes reorganization and it starts with the formation of an 
autophagosome, a double-membrane vesicle that engulfs cytoplasmic components and damaged 
organelles in unselective or selective manner. The membrane is known as autophagophore and it can 
derive from different sources, including the plasma membrane, the endoplasmic reticulum and the 
mitochondrial outer membrane 170. After formation, the autophagosome fuses with lysosome forming 
the autolysosome 166,170. The CMA is the most complex and specific type of autophagy. In fact, only 
specific proteins with the CMA targeting pentapeptide motif KFERQ are recognized by chaperone 
protein Hsc70 (heat shock cognate 70) and translocated to the lysosome for degradation 171. The 
lysosome-associated membrane protein (LAMP-2A), a receptor on the lysosome membrane, 
recognizes the target protein and mediates the translocation into the vesicle for degradation 172. The 
fate of the cargo is the same regardless the type of autophagy involved. In fact, the cargo is degraded 
by lysosomal enzymes and the resulting molecules (amino acids, nucleotides, fatty acids) are then 
released into the cytoplasm and recycled as building blocks in different anabolic pathways, such as 
protein synthesis, nucleic acid synthesis, gluconeogenesis and fatty acid synthesis 163. Autophagy can 
be classified as selective when specific targeted cargo are delivered for degradation and as non-
selective, that is responsible for turnover of bulk cytosolic components 173.  
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In normal conditions, cells maintain a basal constitutive level of autophagy which ensures the proper 
intracellular elimination of aberrant organelles and protein aggregates, thus preserving cell 
homeostasis 174. However, cells can further activate autophagy under stress conditions such as nutrient 
deprivation, oxidative stress, hypoxia and drug treatment in order to prevent stress-induced death 175-
177. The relevance of the process for the intracellular quality control is emphasized by the fact that 
autophagy is an evolutionarily highly conserved process, that occurs also in other eukaryotes such as 
the yeast Saccharomyces Cerevisiae. In fact, more than 30 autophagy-related genes (Atg) have been 
identified in yeast and most of them are conserved also in multicellular eukaryotes such as mammals 
178. Most of the ATG genes discovered have been well characterized during the past years and they are 
necessary for the regulation of the 4 different phases of this dynamic process: induction, 
autophagosome nucleation, autophagosome elongation and completion (Fig. 4).  
 
 
 
Figure 4. Autophagy phases. Vesicle nucleation: formation of the phagophore. Vesicle elongation: expansion 
of the phagophore into an autophagosome which engulf the cargo. Docking and fusion step: autophagosome 
fuses with a lysosome forming the autolysosome. Vesicle breakdown and degradation: the sequestered material 
is degraded inside the autolysosome and recycled (Figure by Meléndez and Levine, 2009) 179. 
 
Induction of autophagy. In this phase nutrient sensors drive the recruitment of multiple ATG proteins 
in order to enable autophagosome formation. 
The ULK protein complex is responsible for the initiation of the process and it is composed of Unc-51 
like autophagy activating kinase 1/2 (ULK1/2), autophagy-related gene 13 (ATG13), autophagy-
related gene 101 (ATG101) and FAK family kinase-interacting protein of 200KDa (FIP200) 180. The 
initiating complex activation is regulated by stress factors which influence the 5' adenosine 
monophosphate-activated protein kinase (AMPK) and the mechanistic target of rapamycin Complex 1 
(mTORC1) pathways, both sensors of the energy status of the cell. AMPK is a nutrient sensor 
activated by allosteric binding of AMP to its activating sites. MTORC1, the major negative regulator 
of autophagy, is a complex characterized by mTOR, regulatory-associated protein of mTOR (raptor), 
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mammalian lethal with SEC13 protein 8 (MLST8) and other non-core components. It is regulated by 
tuberous sclerosis complex 1/2 (TSC1/2) that is a GTPase activating factor and it is active in normal 
nutrient conditions. Low energy levels in the cell lead to reduction of intracellular ATP and increase 
of AMP, leading to activation of AMPK. Active AMPK phosphorylates TSC2 and activates the 
TSC2/TSC1 complex that in turn inactivates mTORC1. In fact, in normal nutrient condition mTORC1 
is active and directly binds (through raptor), phosphorylates and inactivates ULK1/2, leading to 
autophagy inhibition. However, during nutrient deprivation mTORC1 is inhibited and released from 
the complex, therefore ULK1/2 can be activated by dephosphorylation. Active ULK1/2 phosphorylate 
ATG13 and FIP200, which translocate the complex to the pre-autophagosomal membrane thereby 
inducing the autophagic process 170,181,182.  
 
Vesicle nucleation and cargo sequestration. In this phase lipids and proteins necessary for the 
autophagosome membrane formation are recruited in order to initiate the phagophore formation 148.  
The protein complex Beclin1 and vacuolar protein sorting 34 (VPS34) are involved in the vesicle 
nucleation.  
The class III phosphatidylinositol 3-kinase (PtdIns3K) protein VSP34, regulated upstream by the ULK 
complex, leads to production of phosphatidylinositol-3-phosphate (PI3P), essential for elongation and 
recruitment of other ATG downstream proteins involved during vesicle elongation. Beclin-1 and 
VPS34 interaction is responsible for VSP34 activation and for increased levels of PI3P. However, 
more regulatory proteins are involved 181,183. Autophagy/beclin-1 regulator 1 (AMBRA1), ATG14L, 
ultraviolet irradiation resistance associated gene (UVRAG) and Bax-interacting factor 1 (BIF1) induce 
autophagy: BIF1 interacts with Beclin-1 through UVRAG and enhances class III PI3K enzymatic 
activity while AMBRA1 is phosphorylated and activated by ULK1 to promote the recruiting and 
activation of VPS34 184.  On the other hand, Rubicon and Bcl-2 inhibit autophagy. For instance, Bcl-2 
BH3 domain interacts with Beclin-1 destroying the interaction with VSP34 and leading to the 
inhibition of the autophagic process 185.  
 
Vesicle maturation. In this phase the phagophore expands and closes forming a mature double 
membrane autophagosome 175.    
The vesicle elongation is controlled by two ubiquitin-like conjugation systems that play a fundamental 
role in the phagophore formation 182. The first conjugation is characterized by the covalent bond of the 
ubiquitin-like protein ATG12 and ATG5 through the activity of ATG7 (E1 like-enzyme) and ATG10 
(E2 like-enzyme). Subsequently, the ATG12–ATG5 conjugate interacts non-covalently with ATG16-
like 1 and promotes the second conjugation reaction acting as E3-ubiquitin like ligase 181,183. The 
second conjugation occurs between phosphatidylethanolamine (PE) and microtubule-associated 
protein 1A/1B-light chain 3 (MAP1LC3 or simply LC3) through the activity of different enzymes 182. 
LC3 protein is synthetized as precursor pro-LC3 and converted by protease ATG4 to the cytosolic and 
soluble form LC3-I while LC3-I is lipidated to insoluble and membranes associated LC3-II form 
through ATG7 and ATG3 (E2 like-enzyme) activity. LC3-II is associated to autophagosomes 
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membrane and necessary for maturation and cargo sequestration 186.  Eventually, LC3-II associated to 
the membranes is degraded along with the cargo during the last step of the process 187.  
The recognition, sequestration and recycling of specific ubiquitinated proteins through the autophagic 
process are partially controlled by sequestosome 1 (SQSTM1 or p62) 188. SQSTM1 is a 
multifunctional scaffold and adaptor protein with three different domains: a carboxy-terminal 
ubiquitin-associated domain for interaction with ubiquitinated proteins168, a Phox and Bem1 (PB1) 
domain for self-oligomerization 168 and an LC3-interacting region for the binding with LC3-II on 
autophagosome membranes 189.  
 
Lysosome fusion. In this phase the mature autophagosome fuses with lysosome to form an 
autolysosome, a single membrane vesicle that degrades the inner autophagosome membrane and the 
cargo through the activity of lysosomal enzymes such as lysosomal acid hydrolases and cathepsins 182. 
The fusion of autophagosomes and lysosome is driven by a small Rab GTPases protein (Rab7), by the 
homotypic fusion and protein sorting (HOPS) complex and by lysosome-associated membrane protein 
2 (LAMP-2). LAMP-2 is a membrane glycoprotein associated to lysosome, it exists in 3 forms 
(LAMP-2A, LAMP-2B and LAMP-2C) and it plays an important role in CMA 172,190. Moreover it has 
been reported that Pleckstrin homology domain containing protein family member 1 (PLEKHM1) 
directly interacts with HOPS and LC3 on autophagosome membranes and mediates the binding 
necessary for the fusion. In fact, the alteration of PLEKHM1 blocks the lysosomal degradation of the 
cargo 191,192. 
 
1.5.1.1   AUTOPHAGY IN CANCER 
Autophagy is important in physiological conditions like aging and stress adaptation but it plays 
fundamental roles also in several pathological conditions. Due to its important role in regulation of 
cell homeostasis, defects in the autophagy machinery have been associated to the onset of different 
disorders 193. For instance, in neurodegenerative processes impaired autophagy leads to toxic 
accumulation of mutated protein forms such as mutant Huntingtin (mHtt) and α-synuclein, 
respectively responsible for Huntington´s and Parkinson’s disease 194,195. Therefore, functional 
autophagy exerts a protective role against neurodegenerative processes 196. However, in cancer, 
autophagy shows a controversial involvement due to a context-dependent role with cancer-promoting 
and cancer-suppressing functions 197. In fact, in early stages of tumorigenesis autophagy may prevent 
cancer development (for instance by limiting genome mutations and chronic inflammation) while in 
established tumors it promotes tumor cell survival and tumor growth, likely by aiding cells to cope 
with stress conditions such as hypoxia, oncogenic stress and anticancer treatment 198.  
Several evidences confirm the tumor-suppressive function of basal levels of autophagy and its 
correlation with cancer in case of deregulation 199. Many autophagy related genes with a tumor 
suppressor function have been correlated to cancer: UVRAG deletion is common in colon carcinoma 
200, LC3 gene locus is frequently founded deleted in liver, breast and ovarian cancer 201 and ATG5 and 
ATG7  deletion cause liver tumor in mice 202. The onset of DNA mutations and the immune response 
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are two mechanisms that explain how impaired autophagy may promote tumor initiation. In fact, 
autophagy is responsible for degradation of cellular components such as damaged mitochondria, 
thereby regulating the production of ROS which are a threat for the cells due to their mutagenic 
capabilities. Therefore, a defective catabolic process leads to accumulation of the cellular waste and 
altered DNA which in turn trigger an inflammatory response and altered gene expression and so 
promoting tumor formation 198.  
On the other hand, autophagy holds a tumor-promoting function in already established tumors since 
it provides a selective advantage during stress conditions. In fact, as previously described, high 
proliferating tumors are characterized by increased metabolism which combined with low 
vascularization and perfusion contributes to the formation of a toxic microenvironment: hypoxic, acid 
and devoid of nutrients 203. In such a hostile condition, cancer cells with a functional and upregulated 
autophagy are able to adapt and survive escaping apoptosis. HIF1α activation, following the oxygen 
deprivation, activates autophagy through AMPK kinase activity and BNIP3/BNIP3L induction 204-207. 
Increased levels of ATG5, a key regulator of autophagosome development, were found in breast 
cancer cells cultured in low pH conditions, suggesting autophagy as an adaptive mechanism in acidic 
conditions 148. Finally, nutrient deprivation is a main positive regulator of autophagy 208. Increased 
levels of autophagy have been observed and correlated to poor prognosis in some types of cancers 
209,210. Furthermore, the involvement of autophagy in drug resistance is of great clinical relevance. 
Several studies have shown the ability of cancer cell to induce the autophagic response as an adaptive 
mechanism to respond to cytotoxicity of chemotherapy and radiation 211. In fact, the activation of the 
catabolic process is necessary to get rid of drug-induced damaged molecules, allowing tumor cell 
survival and proliferation. In this context, inhibition of autophagy has been correlated to an increased 
sensitivity of cancer cells to chemotherapies, in fact the use of autophagy inhibitors improved the 
therapeutic effects of several conventional chemotherapic drugs such as 5-FU 212-215, docetaxel and 
cisplatin 176,193,205,216.  
The dual role played by autophagy in tumor biology provides the possibility to consider new 
approaches for cancer therapy and prevention 197. From one hand the tumor suppressor activity of 
autophagy might be considered as a strategy for cancer prevention 212. On the other hand, more 
interesting and likely feasible is the possibility to use autophagy inhibitors to reduce the ability of 
cancer cells to adapt to stressful conditions, like hostile microenvironment and drug cytotoxicity, 
reducing the resistance mechanisms responsible for tumor relapse 217. Therefore, the combination of 
conventional chemotherapeutic drugs and autophagy inhibitors has been considered as a new 
therapeutic strategy to improve therapeutic efficacy and induce regression of established tumors. 
 
1.5.1.2   TARGETING AUTOPHAGY IN CANCER 
Several autophagy inhibitors are available and they can be classified according to the process phase 
that they can target. Early-stage autophagy inhibitors are 3-methyladenin (3MA), LY294002 and 
wortmannin which target PI3K, thereby interfering with the induction of the process 218-220. Moreover, 
NSC185058 and NSC377071 target ATG4 suppressing the activation of LC3, the small molecule 
SBI-0206965 can selectively inhibit ULK1 kinase and several different small molecules such as 
SAR405 are able to inhibit VPS34 221-224. Late-stage inhibitors include bafilomycin A1 (BafA1) and 
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concancamycin as inhibitors of lysosomal vacuolar H+-ATPase, E64D and Pepstatin A as inhibitors of 
lysosomal proteases 212,225,226 and Chloroquine (CQ) as inhibitor of the lysosomal activity.  
 
CHLOROQUINE 
CQ and its derivative Hydroxychloroquine (HCQ) are the only autophagy inhibitors used in clinical 
trials for treatment of solid tumors 227. Both molecules belong to the 4-aminoquinoline class of 
antimalarial drugs exploited for 70 years to prevent and treat infection of Plasmodium falciparum, the 
parasite responsible for malaria 228. When the parasite digests the hemoglobin into the digestive 
vacuoles, it releases the toxic ferriprotoporphyrin IX that is removed in normally conditions. 
However, CQ accumulates into acidic cellular compartment (after protonation), binds the porphyrin 
and prevents its degradation, leading to plasmodium cell death 229. More recently, CQ has been used 
for treatment of autoimmune diseases such as rheumatoid arthritis and lupus erythematosus because of 
its immune suppressive activity 230,231. Finally, CQ is also able to inhibit autophagy due to its 
lysosomotropic activity which increases lysosomal pH and alters lysosomal function 232,233.  
CQ is a weakly basic tertiary amine that can exert an anticancer activity with multiple mechanisms of 
action still under investigation. Different studies have described its ability to block cell cycle and 
induce apoptosis but anticancer activity might be more correlated to its lysosomotropic activity which 
mediates radio-sensitization and chemosensitization 233,234. According to the type of tumor, 
microenvironment and immune system, CQ generally can have different effects: autophagy inhibition, 
apoptosis induction, interaction with nucleotides, multidrug resistance pumps inhibition, improving 
drug uptake, and interfering with the immune system 233.  
CQ inhibits autophagy. As a weak base with pKa 8.2, CQ is found mostly in the protonated form in 
acidic compartments 235. Therefore, when it enters the lysosome, it is trapped within the lysosomal 
lumen, blocking lysosomal function and the degradation of the cargo of autolysosomes. The major 
limitation for CQ as autophagy inhibitor in clinical oncology is correlated to the dose. Low CQ 
concentrations inhibit autophagy in cancer cell lines in vitro but not on primary cell lines 236. For 
malaria the therapeutic dose is 5 mg/kg and it could increase up to 10 mg/kg. However, above 
20 mg/kg, CQ can cause serious toxic effects like retinopathy and doses higher than 86 mg/kg are 
lethal 237. Several in vivo studies showed that high CQ doses are required to inhibit tumor growth and 
autophagy in mice but for instance, it has been also shown that the co-treatment of low doses of CQ 
(3,5 mg/kg) and bevacizumab delays tumor growth in human xenograft model 233,238. The high 
variability of the efficacy observed in mice xenografts might be correlated to the different capacity of 
various tumor models to accumulate CQ at the effective concentration to inhibit autophagy 217,238. 
Therefore, CQ is not used alone in cancer treatment but in combination with conventional chemo and 
radiotherapies in order to reach synergic affects 239,240. CQ and HCQ showed ability to induce 
apoptosis at doses higher than 30 µM in different cell lines 241,242. Treatment with HQ showed 
lysosome membrane permeabilization followed by release of lysosomal enzymes, such as cathepsins. 
As a consequence of the lysosomal membrane disruption, mitochondrial membrane permeabilization 
occurs and it triggers the mitochondrial apoptotic pathway through Cytochrome C release 238. It has 
been also shown that CQ stabilizes p53 and induced p53-dependent pathway apoptosis 233. CQ kills 
cancer stem cells. CSCs are considered the most difficult cell population to kill because of their 
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resistance to chemotherapy. However, low doses of CQ inhibited the in vitro formation of 
mammospheres of breast and pancreatic cancer while the same doses were not toxic on non-cancer 
stem cells 236,243. A potential role of CQ on survival pathways in CSCs has been suggested, such as 
impairment of C-X-C chemokine receptor type 4 (CXCR4) signaling or inhibition of hedgehog 
pathway 236. CQ interacts with nucleotides and at high doses interfering with DNA and RNA 
synthesis. In fact, CQ is able to bind nucleotides, especially purines, forming complexes which 
prevent the integration on the nucleotides itself into the acids nucleic 244,245. CQ is a pleiotropic drug 
due to its ability to induce or inhibit cancer cell growth according to different doses and cell lines 246.  
CQ has also indirect effects in cancer, by interfering with drugs uptake and the immune system. Many 
anticancer drugs, such as doxorubicin and mitoxantrone, are weak bases as well as CQ and they are 
likely protonated in the acidic extracellular tumor microenvironment and in acidic compartments, due 
to the “ ion trapping” effect, responsible for low distribution and reduction of pharmacological effects. 
Therefore the CQ treatment may raise lysosomal pH and facilitate drug retention. Moreover, CQ 
directly binds to MRP reversing the MRP-mediated doxorubicin resistance 247,248. CQ showed also 
ability to stimulate the immune system. The combination therapy of CQ and chemo-radio-therapy 
leads to an increased expression and presentation of MHC-I on tumor cell surface enhancing 
malignant cell death mediated by cells of the immune system 249. On the other hand, high doses of CQ 
showed ability to inhibit cytokine production, such as TNF-α, IL-6, IL-1β, inhibiting the immune 
response 250.  
However, at not toxic concentration (below 20 mg/kg) CQ can only inhibit MRP, interfere with 
immune system and kill cancer stem cells but it does not affect autophagy, apoptosis and nucleotides. 
Therefore, it is suggested that CQ is used in clinic an adjuvant to conventional chemo and 
radiotherapy and that the treatment scheme is specific for each chemotherapeutic regimen 233. 
Preclinical studies on CQ provided conflicting results. In murine c-Myc-induced lymphomas, 
inhibition of autophagy by Chloroquine enhanced the ability of DNA alkylating agent to induce tumor 
cell death and tumor regression 238. Although modest effects were observed on tumor growth in 
xenograft model of pancreatic cancer, a better efficacy was observed in other pancreatic ductal 
adenocarcinomas (PDAC) patient derived xenografts (PDXs) treated with HCQ 239,251-253. Several 
ongoing phase I/II clinical trials are exploring the toxicity of CQ and HCQ in combination with 
conventional chemotherapeutic drugs in different tumors (Tab. 1). Despite some studies have shown 
clinical safety and promising efficacy of HCQ used in combination with chemotherapies, the results of 
different trials showed poor efficacy and several limitations such as the effective achievable doses for 
autophagy inhibition in human tumors 254,255. The study and the development of more potent and 
specific autophagy inhibitors suitable for clinical application in combination with conventional 
cytotoxic agents is warranted because of the limitations observed with the use of CQ and HCQ 217,256.  
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Tumor type Therapeutic combination 
 
Breast cancer  
 
HCQ only 
HCQ + ixabepilone 
Lung cancer  HCQ + gefitinib 
HCQ + erlotinib 
Pancreatic cancer HCQ only 
HCQ + gemcitabine 
Prostate cancer HCQ only 
HCQ + docetaxel 
Multiple myeloma HCQ + bortezomib 
Colorectal cancer HCQ + regorafenib or vorinostat 
Hepatocellular carcinoma HCQ only 
Renal cell carcinoma HCQ only 
HCQ + aldesleukin 
Lymphangioleiomyomatosis HCQ + sirolimus 
Melanoma  HCQ + gefitinib 
Sarcoma HCQ + sirolimus  
Leukemia  HCQ + mitoxantrone or etoposide 
Advanced solid tumors HCQ + sirolimus or vorinostat 
Table 1. Preclinical and ongoing clinical studies using CQ an HCQ in cancer treatments. Phase I/II clinical 
trials using combinations of CQ with different cytotoxic agents are currently being conducted in various tumor 
types. 
 
SALINOMYCIN 
Salinomycin (SAL) is a carboxylic polyether potassium ionophore with antibiotic activity against 
Gram-positive bacteria and it is used in veterinary medicine as anti-cocciostat and as growth 
promoting agent 257. In 2009, Gupta et al. performed a high-throughput screening and they found that 
SAL was able to specifically kill breast CSCs. SAL was found to be 100-fold more potent than 
paclitaxel, the taxol commonly used in breast cancer chemotherapy. Moreover, SAL-treated mice 
showed inhibition of tumor growth and promotion of epithelial differentiation in breast cancer stem 
cells 258. Since then, many studies have focused in understanding the mechanisms by which SAL kills 
cancer cells and CSCs, showing that different pathways are involved. In fact, SAL is able to induce 
apoptosis and overcome MDR in cancer cells expressing ABC-transporters that are responsible for the 
gain of the resistant phenotype 259. SAL showed inhibition of the Wnt/B-catenin pathway, 
fundamental in stem cell development, through inhibition of a Wnt co-receptor phosphorylation in 
chronic lymphocytic leukemia and in hepatocellular carcinoma, thereby leading to apoptosis in cells 
that are dependent on Wnt activity 260,261. SAL reduced the subpopulation of CSCs and induced their 
differentiation in colon carcinoma cells 262. Moreover, SAL is able to sensitize cancer cells to 
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conventional chemotherapeutic drugs, such as doxorubicin and etoposide by promoting DNA damage 
and inhibiting the expression of cell cycle regulators 263. All these findings identify SAL as a new 
promising compound to develop for cancer therapy. Despite it is clear how SAL is toxic to coccidia, 
there is the great need to better understand specific mechanisms of action that make this compound 
toxic on tumor cells 264. 
More recently, SAL showed promising ability to inhibit the late stages of autophagy in breast CSCs 
and in hepatocellular carcinoma promoting cancer cell death through apoptosis 265,266. The explanation 
might be correlated to the critical role of autophagy in promoting the cancer cell phenotype and tumor 
development. In fact, fundamental autophagy related genes, such has Beclin1 and ATG4A are 
necessary for the maintenance of cell stemness and tumorigenicity and the inhibition of the autophagic 
process is correlated to the differentiation on CSCs and the loss of their features 265,267,268. However, it 
has also been reported that SAL is able to induce caspase dependent apoptosis through activation of 
the autophagic process in prostate, colon and breast cancer cells 269-271.   
The major limitation for the potential clinical use of SAL for cancer therapy is the very high toxicity 
264. Despite the specific mechanisms that mediate this toxic effect are unknown, it was reported that 
SAL is highly toxic on dorsal root ganglia and Schwann nervous cells which die through apoptosis 272. 
Clinical pilot studies of ovarian, neck and breast cancer patients treated with 200-250 mg/kg of SAL 
every second day for 3 weeks showed neither acute side effects nor long-term complication but a 
promising inhibition of the cancer progression 273. Nevertheless, studies aiming at the synthesis of 
SAL derivatives are ongoing with the prospective to develop less toxic molecules with a better 
biological activity 274-276.  
 
1.5.2   THE UBIQUITIN PROTEASOME SYSTEM (UPS) 
The fundamental role of the UPS pathway in proteins turnover was discovered 30 years ago and 
provided a mechanism that explains how cells maintain a balance between protein synthesis and 
degradation 277. The UPS is involved in the specific degradation of most of damaged proteins, such as 
product of oncogenes and tumor suppressors, that need to be removed in order to keep proper 
intracellular homeostasis 278. Therefore, an altered UPS pathway is correlated to the onset of different 
disorders such as neurodegenerative disease and cancer 165,279,280. 
The proteasome is a highly evolutionarily conserved complex able to recognize proteins that need to 
be degraded and the substrate identification is highly specific due to the ubiquitination process. Only 
proteins tagged with poly-ubiquitin chains are delivered to the proteasome for removal 281. Ubiquitin 
(Ub) is a small and highly conserved regulatory protein of 76 amino acid including 7 lysine residues.  
Ubiquitination is a multi-step process regulated by 3 different enzymes: the Ub-activating (E1), the 
Ub-conjugating (E2) and the Ub-ligating (E3) which catalyse the Ub activation and the binding to 
substrates 278. The process is reversible and the Ub removal is controlled by specific deubiquitinating 
enzymes (DUBs), such as USP14 and UCHL5 282. Three different types of ubiquitination exist:  
mono-ubiquitination (one Ub is attached to substrate), poly-monoubiquitination (several different 
mono-ubiquitin are bound to proteins) and poly-ubiquitination (substrates are linked to chains formed 
by several units of Ub). According to the different types of ubiquitination proteins undergo to different 
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cellular process and a chain of at least 4 Ub is necessary in order to obtain an effective degradation 
278,283. The linkage among the several Ub units involves the lysine residues and according to the 
specific lysine involved the tagged proteins are destined to different cellular fate. The Lys-K48 poli-
ubiquitination is very specific target for protein degradation through the proteasome while Lys-K63 
poli-ubiquitination is correlated to DNA repair and replication as well as protein degradation through 
proteasome pathway or autophagy 284-286.  
The UPS is an important pathway for many physiological processes like cell proliferation and cell 
death, protein quality control, protein aggregation and response to oxidative stress. The proteasome 
controls the destine of several fundamental players of cell cycle (cyclins), pro-apoptotic proteins 
(Bax), NF-kB, and tumor suppressor protein (p53), deciding whether the cell has to die or proliferate 
287. Moreover, the UPS is responsible for the degradation of damaged and non-functioning proteins 
modified by oxidation due to ROS accumulation 288. Thus, deregulation of the UPS and, in particular 
its upregulation have been observed in cancer cells that are thereby more sensitive to its blockade due 
to the fact that they rely more on proteasome function than normal cell 289. For these reasons, the UPS 
is a new therapeutic target in cancer therapy and Bortezomib (trade name Velcade®), a synthetic 
dipeptide boronic acid is the first proteasome inhibitor approved by FDA for the treatment of multiple 
myeloma 50.  
 
1.6   SCREENING MODELS FOR ANTI-CANCER DRUG DISCOVERY 
The drug development process consists of several phases. Potential compounds are identified 
exploiting different types of screening models and introduced into clinical use after proper pre-clinical 
studies aimed at assessing the safety of the molecule. However, the number of drugs that eventually 
enter the clinic for cancer treatment is much lower than the total numbers of compounds obtained 
from initial screening phases and a main raison is correlated to the failure of in vitro preclinical 
models in representing the complex physiological in vivo conditions of the tumor mass.  
The possibility to consider human tumor cell lines a useful tool for large-scale screening dates back to 
1985, whereas human tumor xenografts had been the mainstream strategy exploited in anti-cancer 
drug discovery. The advantages of the new system consisted in the possibility to asses a larger number 
of compounds on a broader panel of human tumor cell lines in a shorter lapse of time. Subsequently 
only hit molecules would have been tested on mouse model for the preclinical evaluation 290,291. Drug-
screenings for anti-cancer drug discovery have been classified into empiric, based on cellular 
cytotoxicity assays, and mechanistically, exploiting specific molecular targets for cancer cells. The 
first type has been providing a great number of different hit compounds but with a mechanism of 
action limited to the non-specific ability to induce DNA damage. Conversely, new drug screenings 
models considering specific features of cancer cells have been developed and exploited leading to 
more successful compounds due to their higher selectivity towards malignant cells 292.  For instance, 
the screening for protein kinase inhibitors led to the identification of the lead compound that 
subsequently was modified into Imatinib, nowadays used for cancer treatment 293. Despite their 
specificity, target-based screenings are not predictive of the effect of the compound in the more 
complex cellular system where other physiological factors can interact with drug activity.  
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Therefore, there is a need for drug screening strategies that can take into account the complexity of the 
whole tumor tissue, including for example hypoxia, starvation and metabolic factors. For instance the 
screening of drug libraries exploiting the multicellular tumor spheroids (MCS) model, tumor stem 
cells or glucose starved tumor cells has contributed to the identification of promising therapeutic 
molecules particularly active on cancer cells responsible for tumor relapses 294.  Unlike classical 
monolayer cell cultures, MCS is in vitro 3D model better resembling the tumor mass properties, such 
as hypoxia, acidosis and nutrient deprivation as well as the limited drug penetration 295. MCS have 
been used as a promising tool for drug screening. In fact, it has been suggested that compounds 
showing cytotoxicity on MCS will also be effective on solid tumor in vivo 296-298.  Moreover, MCS are 
characterized by external layers of more proliferating cells and by a central core of quiescent slow 
proliferating cells. These latter are considered responsible for chemoresistance and compounds able to 
kill them in MCS model are most likely capable to target them in vivo 299,300. 
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2 AIM OF THE THESIS 
 
The project of this thesis mainly focuses on the role of acidic tumor microenvironment on malignant 
progression and therapy. The major aims are to better understand which molecular mechanisms some 
cancer cells exploit to overcome stress induced by acidosis and to identify and possibly develop 
therapeutic strategies to target cancer cells in acidic environment.  
Particularly, a part of the project aimed at investigating the role of autophagy in acidic stress (Paper 
I). It has been shown that tumour acidity and autophagy are both correlated somehow to malignant 
progression and poor outcome. Therefore, the purpose was to define whether exposure of cancer cells 
to acidic culture conditions affected the autophagic process. We found that autophagy is a survival 
mechanism for tumor cells in acidic conditions, further strengthening the idea of autophagy inhibition 
as therapeutic strategy. However, we found that Chloroquine, the only autophagy inhibitor used in 
clinical trials does not inhibit autophagy and is not cytotoxic in cancer cells in acidic conditions 
(Paper II). Therefore, we aimed at identifying other compounds able to inhibit autophagy during 
acidosis. We found that Salinomycin is a potent autophagy inhibitor in the acidic tumor 
microenvironment (Paper III). 
The second part of the project is focused on the identification of compounds with anticancer activity 
through a novel model of drug screening (Paper IV). In fact, most of the drug-screening assays for 
discovering of anticancer drugs are performed in neutral pH and normoxic culture conditions while 
cancer cell microenvironment is known to be acidic and hypoxic. This limitation could be one of the 
reasons for lack of efficacy for many drugs used in clinical oncology. So a drug screening performed 
in acidic and hypoxic conditions might lead to identify new and more effective drugs able to target 
acidic and hypoxic cells potentially responsible for tumor relapses after therapy. 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I: AUTOPHAGY IS A PROTECTIVE MECHANISM FOR 
HUMAN MELANOMA CELLS UNDER ACIDIC STRESS. 
 
Background 
Solid tumors are complex systems of different type of cells and several physical-biochemical factors 
that together characterize the tumor microenvironment. Cancer cells switch their metabolism from 
the oxidative phosphorylation to glycolysis even in normal oxygen pressure, leading to an increased 
production and accumulation of metabolic acids. To avoid cytosolic acidification, cells activate 
proton extrusion mechanisms leading to extracellular acidification, which correlates with 
chemoresistence, proliferation, angiogenesis and ECM degradation. Autophagy is a fundamental 
cellular process induced as a survival mechanism by different stress factors, such as starvation, 
hypoxia, ER stress and DNA damage.  
 
Results 
1. Human Melanoma cells survive and proliferate in acidic pH 
We assessed cell viability over 72 hours of five different Melanoma cell lines and observed that all 
cell lines survived and showed a decreased proliferation when cultured at low pH (pH 6.8 and 6.5). 
Among the cell lines analysed, Me30966 maintained a rather normal proliferation rate even in 
acidic conditions. 
 
2. Human melanoma cell up-regulate autophagy and maintain a functional autophagic flux in 
acidic pH (acute and chronic exposition) 
Melanoma cells exposed to acidic stress showed increased level of LC3+ puncta, suggesting up-
regulation of basal autophagy. However, increased levels of LC3+ vesicles could be also correlated 
with a defective degradation of autophagosomes. Therefore, in order to confirm that cells cultured 
under acidic stress could really up regulate autophagy, we looked at the autophagic flux using 
autophagy inhibitors like BafA1. BafA1 is able to block the latest phase of autophagy preventing 
the degradation of the autolysosomes, which therefore accumulates within the cell. Fluorescence 
and Western Blot analyses confirmed increased level of autolysosomes and LC3-II, indicating the 
presence of a functional autophagic flux. These findings were observed both in case of transient 
exposure of parental cancer cells to acidic pH (8 hours) as well as in case of chronic exposure 
(using a cell line which has been adapted to pH 6.8). 
 
3. Human melanoma cell decreases nutrients uptake and ATP content in acidic pH 
In acidic stress, melanoma cells reduced the uptake glucose and of the amino acid leucine. Lower 
levels of intracellular glucose were confirmed by the reduction of the cell ATP content, probably 
due to the reduction of glucose consumption and inhibition of glycolysis. 
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4.  Acidic pH induces cytosolic acidification and inhibition of mTOR signalling 
Melanoma cells showed a reduction of the cytosolic pH within few minutes after exposure to acidic 
medium. MTOR is a nutrient sensor and it is inhibited during stress conditions (like starvation), 
leading to the stimulation of autophagy. We observed that at low pH culture conditions the mTOR 
pathway is inhibited. Western Blot data showed a reduction of phosphorylated p70S6K and 4EBP1, 
two mTOR downstream effectors.  
 
5. Autophagy is crucial for survival of melanoma cells under acidic stress 
We investigated the effects of autophagy inhibition on cell death at different pH conditions. The 
knockdown of ATG5 induced augmented cell death in those cells that were exposed to low pH 
culture conditions as compared to cell cultured at pH 7.4. These data confirm that proficient 
autophagy is needed for melanoma cells to survive during acidic stress.  
 
Significance 
We showed that autophagy is an important protective mechanism for cancer cell to adapt and 
survive under acidic pH. Therefore, autophagy and acidity both represent potential therapeutic 
targets in cancer and combination therapies of autophagy inhibitors with conventional 
chemotherapy represent a feasible therapeutic strategy. 
 
3.2 PAPER II: ACIDIC EXTRACELLULAR PH NEUTRALIZES THE 
AUTOPHAGY-INHIBITING ACTIVITY OF CHLOROQUINE. 
 
Background 
Tumor acidosis is a fundamental mechanism correlated to malignant progression and drug 
resistance. Others and we have shown that autophagy is an important mechanism that cancer cells 
use in order to adapt and survive to the stress induced by acidosis. Therefore, targeting the 
autophagic process is envisaged as promising new strategy in cancer therapy to kill cells adapted in 
acidic pH. CQ is an antimalarial medication and it has been the only anti-autophagic drug so far 
used in combination anticancer therapies in clinical trials. However, in vivo, CQ has not reproduced 
the antitumor effects that have been obtained in models in vitro and in some cases it has been 
associated to a slightly increase of tumor growth. Therefore, we assessed the capability of CQ and 
Lys-01, a novel CQ derivative, to block autophagy under acidic conditions. 
 
Results 
1. CQ is not cytotoxic in vivo and in vitro on colon carcinoma cells  
We assessed the toxicity of CQ in in vivo models of human colon carcinoma xenografts (HCT116 
and HT29) and we observed that tumor growth was not affected in mice treated with CQ. Moreover, 
we evaluated CQ cytotoxicity in vitro on colon carcinoma and melanoma cells and we found that 
cells cultured at low pH were completely insensitive to CQ. 
 
 28 
2. CQ does not block autophagic flux in cells under acute acidic stress  
We evaluated the actual ability of CQ to block autophagy in transient acidic conditions by assessing 
the changes in expression of the autophagic marker LC3-II. In presence of CQ, high levels of LC3-
II were detected in cells cultured at physiological pH as predicted but the levels of LC3-II were 
unchanged in different cell lines cultured at pH 6.8 and pH 6.5 for 24 hours. These findings 
suggested that CQ does not block the autophagic process in different cancer cell lines during acidic 
stress. 
 
3. CQ does not block autophagic flux in cells under chronic acidosis 
We found that CQ does not block autophagy also in melanoma and colon carcinoma cells that have 
been adapted to growth a pH 6.8 (chronic acidosis). However, when neutral pH conditions were 
restored in these cells, CQ treatment was able to lead again to autophagy inhibition, meaning that 
pH is a main factor affecting CQ activity. Acid-adapted cells are also resistant to the cytotoxicity of 
CQ since we did not detect any reduction in cell viability after treatment even with high CQ doses. 
However, when physiological pH was re-established in culture even acid-adapted cells showed to 
be sensitive to the toxicity of CQ. 
 
4. Autophagy inhibition by Lys-01 is detectable at acidic conditions 
Lys-01 is a CQ dimer reported to be a better autophagic inhibitor. We found that Lys-01 is able to 
inhibit autophagy even at pH 6.8, unlike CQ. However, the LC3-II accumulation was reduced in cells 
treated with Lys-01 at lower pH, suggesting a pH-dependent activity of this compound. We wondered 
whether this was related to a different cellular uptake of the molecules, especially at acidic conditions, 
due to the different chemical properties as a basic or acid. We performed HPLC in order to quantify 
the cellular content of the 2 compounds after treatment and found that at pH 7.4 Lys-01 accumulates 
at higher levels as compared to CQ, thus possibly explaining its better activity. At pH 6.8, a CQ 
concentration was 7-fold lower than at normal pH while Lys-01 content was about 2-fold lower but 
still significantly higher than CQ. 
5. CQ effect on autophagy in vivo 
In vivo, CQ administration to human colon carcinoma xenografts did not lead to reduction of tumor 
growth. Thus, we performed IHC analysis on HCT116 tumor sections from mice untreated and 
treated with CQ in order to check any possible change in the autophagic process that could explain 
the lack of efficacy. We performed staining with CA9 to identify putative acidic regions (carbonic 
anhydrase 9 is highly expressed in hypoxic regions characterized by extracellular acidification) and 
LC3 to detect modulation of autophagy. In untreated mice, we observed that normoxic areas close 
to blood vessel showed low level of CA9 expression and LC3 while hypoxic areas with high CA9 
expression showed an increased LC3 expression, suggesting that autophagy is more activated. This 
set of data confirmed that autophagy might be upregulated in hypoxic and acidic areas. Effective 
CQ treatment is expected to induce a further increase in the LC3 signal intensity due to a block of 
LC3-II degradation. In fact, CQ treatment leads to a 5-fold increase, as compared to the untreated 
tumors in LC3 expression in normoxic areas close to blood vessels but only a 1.4 increase in the 
hypoxic and acidic areas. 
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Significance  
Autophagy inhibition is being tested as a new strategy in combination cancer therapy. However, we 
showed here that the only autophagy inhibitor currently used in clinical oncoloy does not actually 
inhibit autophagy in acidic conditions. Our findings may partly explain the modest CQ efficacy shown 
in the first clinical trials and underline the need to find and characterize more effective autophagy 
inhibitors. 
 
Figure 5.  CQ does not inhibit autophagy in the acidic tumor microenvironment resulting in the loss of its 
cytotoxic activity.   
 
3.3 PAPER III: TUMOR ACIDOSIS ENHANCES AUTOPHAGY 
INHIBITION BY SALINOMYCIN ON CANCER CELL LINES 
AND CANCER STEM CELLS. 
 
Background 
Cancer cells exploit autophagy during acidosis in order to adapt and survive to the hostile 
microenvironment that characterizes solid tumors. Despite autophagy inhibition has been considered a 
therapeutic strategy in cancer, so far only CQ and HCQ are approved in clinical trials. Unfortunately, 
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it has been shown that CQ is effective only in some models while it has no effect in others, sometimes 
even increasing tumor growth. Moreover, CQ may have autophagy-independent effects. In paper II 
we showed that CQ does not inhibit autophagy in tumor cells exposed to acidic environment, probably 
due to its chemical properties as a weak base. The need to find new autophagy inhibitors led us to 
identify Salinomycin as a potent compound that is active also during acidosis not only in cancer cell 
lines but also in breast cancer stem cells.  
 
Results 
1. Salinomycin is a potent autophagy inhibitor in acidic conditions (transient and chronic 
acidosis) 
HOS cells stably transfected with a GFP-LC3 vector were treated with Sal in presence and absence of 
lysosomal inhibitor BafA1 and in medium buffered at pH 7.4 and 6.8. The accumulation of GFP-LC3-
positive autophagosomes was assessed by flow cytometry and showed that when cells were cultured 
at pH 6.8 Sal was able to block completely the autophagic flux.  
We confirmed the autophagy inhibiting activity of SAL on AA-HCT116 and AA-Me30966 cell lines 
adapted to pH 6.8. The co-treatment with BafA1 did not further increase the amount of LC3-II in 
SAL-treated cells, demonstrating that SAL blocks the autophagic flux. The strong autophagy 
inhibiting activity was also detected in HCT116 and Me30966 that were transiently exposed to 
medium at pH 6.8 and 6.5. 
2. Salinomycin inhibits autophagy in the core of multicellular spheroids (MCS)  
MCS are a 3D culture model that more closely reproduce in vitro some features that characterize a 
solid tumor mass. It has a central acidic and hypoxic core and a peripheral layer of cells growing in 
oxygen- and nutrients-rich environment. We obtained MCS from HCT116 and we treated them with 
BafA1, CQ, Lys-01 and Sal and performed IHC evaluating the LC3 pattern distribution. We 
observed that MCS treated with CQ and Lys-01 showed LC3 accumulation only in the peripheral 
layer but not in the core while MCS treated with Sal revealed a more homogeneous LC3 
distribution as also occurring in the positive control treated with BafA1. 
Viability and clonogenic assays done on MCS indicated that Sal has a strong cytotoxic effect. 
3. SAL blocks the autophagic flux in cancer stem cells  
CD24+ (non-CSC) and CD24low (CSC) HMLER cells were transfected with tandem probe RFP-
GFP-LC3 that allows the identification and quantification of autolysosome (GFP- RFP+) and 
autophagosomes (GFP+ RFP+).  We found that Sal treatment induced accumulation of 
autophagosomes without significant changes in autolysosomes in both cell lines, especially in those 
cultured at pH 6.8, suggesting a decreased autophagic flux. Moreover, WB analysis showed that lower 
doses of SAL are sufficient to block the autophagic flux in CD24low cells as compared to CD24+ 
cells both at pH 7.4 and pH 6.8.  
4. Acidosis enhances the ability of salinomycin to kill cancer cells and cancer stem cells 
We performed viability assays on HCT116 and Me30966 cultured at pH 7.4 and the respective 
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sublines adapted at pH 6.8 to understand whether the autophagy inhibiting activity of SAL at low pH 
is correlated to an increased cytotoxicity. SAL showed an increased cytotoxicity in low pH-adapted 
cells with a 10-fold difference in IC50 values. Moreover, we observed that cells cultured at acidic pH 
treated with SAL show a reduced clonogenic cell growth as compared to cells treated at pH 7.4.  
Viability assays also showed that CD24low cells are more sensitive to both Lys-01 and SAL as 
compared to CD24+ cells in physiological culture conditions (pH 7.4), confirming that breast CSCs 
are more sensitive to autophagy inhibition. Moreover, the IC50 of SAL for CD24low cells cultured in 
medium at pH 6.8 was 10-fold lower than that for CD24+ cells, suggesting an even more selective 
effect of SAL on these cells at acidic conditions. 
5. Acidic pH enhances the ability of SAL to inhibit mammospheres formation from breast 
cancer tissue derived stem cells. 
It has been shown that a CSCs property is the ability of cancer cells to form mammospheres in vitro 
168. Therefore, we investigated whether this CSCs feature is affected by the pH-dependent activity of 
SAL. CD24low cells cultured and treated with Sal formed a lower number of mammospheres as 
compared to the untreated cells at pH 7.4. This effect was increased in CD24low cells treated with 
SAL at pH 6.8.  
We confirmed the results obtained with CD24low cells with patient-derived breast CSCs in order to 
understand the potential clinical relevance of our findings. SAL inhibited the formation of 
mammospheres in cells cultured at pH 7.4 in a dose-dependent manner and the ability of SAL to 
inhibit mammosphere formation was dramatically increased at pH 6.8, confirming that SAL has a pH-
dependent activity also on CSC derived from patients. 
6. Salinomycin accumulates at higher concentrations in cells under acidic conditions 
As previously described, CQ is a weak base and in acidic conditions protonated CQ does not easily 
enter cells, thus affecting the autophagy inhibiting activity of the drug itself. However SAL, as a weak 
acid, is protonated in acidic condition and may better cross the plasma membrane. UPLC-MS/MS 
analysis showed that in HCT116, HMLER CD24+ and HMLER CD24low cells the amount of SAL 
accumulating in the cells is significantly higher when cells are cultured in acidic conditions.  
 
 
Significance  
We identified SAL as a potent cytotoxic and autophagy-inhibiting agent whose activity on cancer cells 
and CSCs is further increased by acidosis. 
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3.4 PAPER IV: A DRUG-SCREENING ASSAY ON CANCER CELLS 
CHRONICALLY ADAPTED TO ACIDOSIS IDENTIFIES A NOVEL 
ANTICANCER ACTIVITY FOR VERTEPORFIN. 
 
Background 
Most of drug screenings for identification of anticancer drugs are performed in vitro in culture 
conditions at pH and oxygen levels very different from those observed in the tumor 
microenvironment in vivo. This limitation might be one of the reasons behind the lack of drug 
efficacy often observed in clinical oncology. In order to increase the chances of identifying more 
effective anticancer compounds, we optimized a drug screening performed in acidic and hypoxic 
conditions, with the aim to discover effective drugs targeting quiescent and acidic/hypoxic cancer 
cells, reasonably considered responsible for tumor relapses after therapy. 
 
1. Characterization of the acid adapted colon carcinoma cell line AA-HCT116  
The screening has been performed with HCT116 cells that have been adapted to grow at pH 6.8. We 
found that AA-HCT116 cells are different from the parental cells. They have a different phenotype 
being characterized by a bigger cell size and a more mesenchymal trait. RNA sequencing analysis 
showed also that parental HCT116 and AA-HCT116 cells have a different transcription profile and 
preliminary data also indicate that these cells differ in their metabolism with changes in 
mitochondrial respiratory capacity and glycolytic rates.  
 
2. Screening of the Prestwick library screening  
The drug screening has been performed using AA-HCT116 cells in conditions of hypoxia and 
normoxia and viability was used as a read out. For both conditions we optimized the assay with 
regard to number of cells and serum concentration. Subsequently, we proceeded with the screening 
of the Prestwick Chemical Library, a small library of 1280 compounds already approved by FDA 
and already used in clinical applications for the treatment of different pathologies. Cells were 
treated with compounds at 10 uM and cell viability was assessed after 48 hours with enzymatic acid 
phosphatase assay. Hit compounds were confirmed in dose-concentration assays and 11 out of 1280 
compounds showed a substantial reduction of cell viability in the range 1-10 mM. Furthermore, the 
cytotoxicity of the selected 11 hits was tested in parallel on parental HCT116 cells at physiological 
pH and on hTERT-RPE1 cells (immortalized epithelial cells). Among the 11 hits, only Verteporfin 
(trade name Visudyne®) showed preferential cytotoxicity in AA-HCT116 cells as compared to 
parental HCT116 cells and epithelial cells, suggesting a more specific activity towards cancer cells 
in stressed conditions and the possibility of a therapeutic window. 
 
 
3. VP is more cytotoxic on AA-HCT116 
We confirmed that VP had a stronger cytotoxicity on AA-HCT116 as compared to parental 
HCT116 cells using viability assay, time-lapse microscopy and clonogenic assays. Moreover, we 
observed that ambient light activation of VP during treatment lead to an enhanced cytotoxicity of 
the compound. Finally, we evaluated VP intracellular accumulation by fluorimetric analysis and 
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observed that VP accumulates 3-fold more in AA-HCT116 than in the parental cells, likely because 
of its chemical properties as an acidic molecule (a similar finding was confirmed in melanoma 
cells). 
 
4. VP interferes with polyubiquitinated proteins   
VP is a benzoporphyrin derivative, clinically used in photodynamic therapy for the treatment of 
macular degeneration. It has been previously shown that VP is able to inhibit the early phase of 
autophagy and for this reason we studied whether VP-mediated autophagy modulation was 
associated with higher cytotoxicity in AA-HCT116 cells. Western blot analysis did not show any 
significant change in the turnover of LC3-II, indicating a normal autophagic flux in presence of VP. 
However, we observed the disappearance of the SQSTM1, another autophagy marker, in VP-treated 
samples together with the appearance of correspondent high molecular weight bands. SQSTM1 is a 
protein that shuttles ubiquitinated proteins to autophagosomes for degradation and modifications of 
its structure may alter its function and its role in the UPS pathway. Therefore, we evaluated the 
effects of VP on polyubiquitinated conjugates. In VP-treated samples we detected a shift from K48-
poly-ubiquitination to K63-poly-ubiquitination with a concomitant decrease in the pool of free 
ubiquitin. This alteration was observed at early time points and it was enhanced by light exposure.  
RNA sequencing data showed a clear alteration of UPS related genes in AA-HCT116 cell line as 
compared to parental cells and this might be correlated to the increased sensitivity of AA-HCT116 
cells to the drug. However, we showed that VP does not inhibit the proteasome function in these 
cells.  
 
5. VP and unfolded protein response  
The accumulation of high MW cross-linked proteins, such as SQSTM1, might induce endoplasmic 
reticulum (ER) stress and the activation of the unfolded protein response (UPR) which is a survival 
mechanism involved in the removal of toxic protein aggregates through the activity of glucose-
regulated protein 78 (GRP78). Despite ER stress induced proteins such as C/EBP homologous 
protein (CHOP) and heat shock protein 70 (HSP70) were not altered, GRP78 expression was 
affected upon VP treatment. In fact, GRP78 was induced in HCT116 treated with VP with the 
appearance of high MW bands but not in the respective acidic adapted cell lines.  
 
 
Significance  
 
The drug-screening model that we describe may lead to identify new drugs and/or repurposing 
existing drugs active on cells under metabolic stress. Verteporfin has been already used in a clinical 
trial for pancreatic cancer and we show that it is more cytotoxic on cancer cells adapted to acidic 
pH. However, the potential mechanism of action needs to be further investigated. The screening of 
larger drug-libraries will hopefully lead to find and characterize more compounds able to target 
slow proliferating and therapy resistant acid-adapted cancer cells. 
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4 CONCLUSIONS 
 
Cancer cells up-regulates autophagy as a survival mechanism in order to cope with the toxic 
acidic tumor microenvironment. 
During the past years the metabolic reprogramming of tumor cells has acquired an important role in 
the field of cancer progression and therapy. One consequence of altered metabolism coupled with 
abnormal tumor tissue structure is the development of acidosis. The exposure of cancer cells to 
acidosis has been considered responsible for the acquisition of a more malignant and aggressive 
phenotype for the cells able to adapt, by aiding migration, invasion, metastasis and resistance to 
therapy. Different mechanisms are involved in the adaptation process of the cells to the harsh acidic 
environment and the upregulation of the autophagic process showed to play a fundamental role. We 
showed that human melanoma cells exploit autophagy in order to survive to acidic conditions. 
Therefore, our finding provides an additional support to the use of autophagy inhibitors as a 
therapeutic strategy to target tumor cells that have acquired the ability to adapt to acidosis. However, 
there is a need to identify other molecular mechanisms than autophagy involved during the cancer cell 
adaptation process to acidosis in order to be able to find new targets and develop different therapeutic 
strategies.    
 
The only autophagy inhibitor available in clinic fails to inhibit the autophagic process in acidic 
conditions raising the need for the identification of more effective compounds. 
The autophagic process has been considered a promising therapeutic target under clinical 
investigation. Until now, little results have been achieved in clinical settings regarding the use of 
autophagy inhibitors. In fact CQ and its derivative HCQ are the only drugs used in cancer therapy for 
this purpose, in combination with conventional chemotherapy. However, we show that CQ and HCQ 
fail to inhibit autophagy during acidosis possibly explaining their low cytotoxic effect in some tumor 
models. The acidic tumor microenvironment is responsible for the lower drug penetration through the 
plasma membrane due to protonation of weak base molecules, resulting in a subsequent reduction of 
the therapeutic effective dose in vivo. However, additional molecular mechanisms may be involved in 
the pH-dependent acquired resistance other than the d chemical properties of drugs. Our finding 
provides an explanation for a poor efficacy often observed in CQ and HCQ clinical trials and it 
suggests the need to identify new inhibitors effective during acidosis. Lys-01, a dimeric analogue of 
CQ has been recently claimed as a more potent compound in vitro and in vivo and we correlated this 
finding with its better accumulation in the cells in acidic conditions, therefore resulting in a more 
effective autophagy inhibition. However the use of Lys-01 showed limitations due to a pH dependent 
activity, suggesting that it is not the perfect candidate in such conditions. Conversely, we showed that 
the antimalarial compound SAL inhibits autophagy at low pH conditions, displaying a promising 
toxicity on cancer cell lines and CSCs. The stronger effects observed in acidic conditions might be 
correlated to SAL pharmacological properties as a weak acid that is responsible for an increased 
intracellular accumulation at low pH as compared to cells cultured in physiological pH. However, off 
target effects different than autophagy inhibition need to be further investigated to understand whether 
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there are different mechanisms explaining the stronger activity of this drug in acidic conditions. 
Moreover, less toxic SAL derivatives need to be developed in order to assess its efficacy on cancer 
patients. 
  
A new drug-screening model leads to the identification of new compounds effective in cells 
under acidic stress. 
It is known that most of the anticancer drugs that show a good anticancer activity in vitro show lack of 
efficacy on cancer cells in vivo. One explanation is that cancer cell microenvironment is different and 
more complex than the one reproduced in the laboratory settings. Others and we previously described 
tumor acidosis as cause of drug resistance. The possibility to exploit the hypoxic and acidic conditions 
that characterize solid tumor in vivo for the screening of drug libraries may lead to the identification of 
new anticancer compounds. A further investigation of specific molecular mechanisms of action of the 
hits identifies new therapeutic targets characterizing therapy-resistant cancer cells adapted to acidic 
stress. An attractive strategy that has been considered in the past years to identify new effective 
anticancer drugs is to propose the use of existing compounds already used in clinic with a different 
purpose. Using this approach through the screening of drug libraries expensive and time-consuming 
phases of drug development can be omitted due to the fact that most of the informations required are 
available. In fact, the screening of the Prestwick library, a small library of compounds already 
exploited in clinical applications, led us to the identification of the photosensitizer VP as a promising 
anticancer drug toxic on cells adapted to acidosis. We observed that VP accumulates more in cells 
under acidic conditions but this is not strictly correlated to its cytotoxicity. Despite it has been used 
since many years in clinic for different purposes, VP shows a promising ability to kill cancer cells 
through molecular mechanisms that still need to be fully understood. Preliminary studies indicate 
alterations of the ubiquitinated proteins and activation of the unfolded protein response after VP 
treatment but further studies are needed for its potential use in clinical oncology. 
 
 
 
 
 
 
 
 
 
 
 36 
5 ACKNOWLEDGEMENTS 
 
I would like to thank: 
Angelo De Milito, my main supervisor, thanks you for giving me the opportunity to learn so much 
during these years. You have spent a lot of time teaching me how to be a good scientist and how to 
gain more self-confidence. You have never left me alone in difficult moments when experiments were 
not working as we wanted and especially when I had to prepare presentations. You have always had 
faith in my abilities even when I was the first one not believing in myself. I admire your deep passion 
for science and the way you can handle difficult situations without losing hope. 
Stig Linder, my co-supervisor, thank you for being always so supportive and available for 
suggestions. Despite your busy life, you had always time to tell me how good I was and how nice my 
results looked like.  
Maria Hägg Olofsson, my co-supervisor, thank you for all the help during these years. You have 
always being present anytime I needed help not only for experiments but also for personal problems. 
Thank you for always having my back. 
Pādraig D’Arcy, thank you for watching out for me even though you did not have to, since you are 
not officially my supervisor. You have always been nice to me, helping with experiments and 
entertaining us with your jokes and stories. I am happy that I will have you around in the future. 
Angela Strambi, grazie for teaching me all the aspects of a PhD, both experimental and personal, 
ever since your first day in the lab. 
I would also like to thank all my group members: 
Xiaonan you have been such a fundamental person taking care of all the essential lab duties (now we 
are so lost without you). Thank you for always being positive and cheerful no matter what. Magda, 
ciccia, there are no words that explain how much thankful I am to you for being a fantastic friend 
always ready to listen to all my rambling, especially my complaints. You have always helped to cheer 
me up and looking at the bright side of everything. Ellin thank you for being always available for 
suggestions and clarification on everything whenever I ask. Anytime I need something you stop the 
thing you are doing in order to help me, in particular thanks for the English support.  
Thanks to all previous group members Xin, Slavica, Maria B. and Chitraleka for being always nice 
and helpful with me in the lab. Thanks to the students Sara, Di, Diu Lin and Chiara that helped me 
with experiments and gave me a pleasant teaching experience.   
Thanks to Giuseppe and Laura for giving me the worst and best living experience, respectively. You 
are still part of my best memories here in Stockholm. Sara, we have been spending so much time 
together that is easy for me to consider you a sister. Thank you for all the nice times and experiences 
we had together and for always being present and supporting in the worst moments. Francesca, 
ciccia, thank you for being my rock in many occasions, you are a really good person and a good 
friend, always present and ready to listen to me. I really miss having you around. Jason, cretino, thank 
you for all the time spent together, the good wine and the long talks. It has not been always an easy 
friendship with you but I know that is a real one. Gianvito, thanks for being the best party mate I 
  
37 
could have ever asked for, for feeding me and especially for sharing your beer with me. Mirko, I 
enjoyed spending lazy time with you and talk to you about everything. Ale, thank you for always 
coming downstairs happy and making me laugh. Stefano, thank you for always being nice, helpful 
and good listener anytime I had to vent. Nicoletta, thank you for the good suggestions that you gave 
me as a friend and mentor. 
Thanks to all the nice people that I have met in CCK Hanif, Anna Maria, Rouku, Isabell, Limin, 
Pedram, Christos, Ali, Matheus, Iryna, Elin, My, Sara, Tiago, Sophia, Carina, Arthur, Ran, 
Mercedes, Johanna, Sander, Jelena, Veronika, Katia, Lotte, Dan, Mimmi and Bertha for the nice 
talks and the help during these four years.  
Grazie ai miei cuori italiani Valentina, Cinzia, Vittoria & Vittoria, Paolo, Dionisio, Elena e 
Federico per essermi sempre stati vicini anche a distanza. 
E grazie al mitico Vito per l’essenziale supporto, psicologico e alimentare, che mi hanno permesso di 
arrivare fino a questo punto.   
 
 38 
6 REFERENCES 
 
1 Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000). 
2 Berman, J. J. Tumor classification: molecular analysis meets Aristotle. BMC cancer 4, 10, 
doi:10.1186/1471-2407-4-10 (2004). 
3 Koten, J. W., Neijt, J. P., Zonnenberg, B. A. & Den Otter, W. The difference between benign and 
malignant tumours explained with the 4-mutation paradigm for carcinogenesis. Anticancer research 
13, 1179-1182 (1993). 
4 Nguyen, D. X., Bos, P. D. & Massague, J. Metastasis: from dissemination to organ-specific 
colonization. Nat Rev Cancer 9, 274-284, doi:10.1038/nrc2622 (2009). 
5 Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695, 
doi:10.1016/j.cell.2006.11.001 (2006). 
6 Anand, P. et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25, 
2097-2116, doi:10.1007/s11095-008-9661-9 (2008). 
7 Kast, K. et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and 
ovarian cancer. Journal of medical genetics, doi:10.1136/jmedgenet-2015-103672 (2016). 
8 Cai, Q., Medeiros, L. J., Xu, X. & Young, K. H. MYC-driven aggressive B-cell lymphomas: biology, 
entity, differential diagnosis and clinical management. Oncotarget 6, 38591-38616, 
doi:10.18632/oncotarget.5774 (2015). 
9 Mendoza, P. R. & Grossniklaus, H. E. The Biology of Retinoblastoma. Progress in molecular 
biology and translational science 134, 503-516, doi:10.1016/bs.pmbts.2015.06.012 (2015). 
10 Merino, D. & Malkin, D. p53 and hereditary cancer. Sub-cellular biochemistry 85, 1-16, 
doi:10.1007/978-94-017-9211-0_1 (2014). 
11 Doll, R. & Peto, R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the 
United States today. Journal of the National Cancer Institute 66, 1191-1308 (1981). 
12 Ashford, T. P. & Porter, K. R. Cytoplasmic components in hepatic cell lysosomes. J Cell Biol 12, 
198-202 (1962). 
13 Belpomme, D. et al. The multitude and diversity of environmental carcinogens. Environmental 
research 105, 414-429, doi:10.1016/j.envres.2007.07.002 (2007). 
14 Divisi, D., Di Tommaso, S., Salvemini, S., Garramone, M. & Crisci, R. Diet and cancer. Acta bio-
medica : Atenei Parmensis 77, 118-123 (2006). 
15 Willett, W. C. Diet and cancer. The oncologist 5, 393-404 (2000). 
16 Prueitt, R. L. et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. International 
journal of cancer 120, 796-805, doi:10.1002/ijc.22336 (2007). 
17 Clapp, R. W., Jacobs, M. M. & Loechler, E. L. Environmental and occupational causes of cancer: 
new evidence 2005-2007. Reviews on environmental health 23, 1-37 (2008). 
18 Takada, K. Role of Epstein-Barr virus in Burkitt's lymphoma. Current topics in microbiology and 
immunology 258, 141-151 (2001). 
19 Guan, Y. S., He, Q., Wang, M. Q. & Li, P. Nuclear factor kappa B and hepatitis viruses. Expert 
opinion on therapeutic targets 12, 265-280, doi:10.1517/14728222.12.3.265 (2008). 
20 Takayama, S., Takahashi, H., Matsuo, Y., Okada, Y. & Manabe, T. Effects of Helicobacter pylori 
infection on human pancreatic cancer cell line. Hepato-gastroenterology 54, 2387-2391 (2007). 
21 Karin, M. & Greten, F. R. NF-kappaB: linking inflammation and immunity to cancer development 
and progression. Nature reviews. Immunology 5, 749-759, doi:10.1038/nri1703 (2005). 
22 Sansare, K., Khanna, V. & Karjodkar, F. Early victims of X-rays: a tribute and current perception. 
Dentomaxillofac Radiol 40, 123-125, doi:10.1259/dmfr/73488299 (2011). 
23 Boffetta, P. et al. Occupational X-ray examinations and lung cancer risk. International journal of 
cancer 115, 263-267, doi:10.1002/ijc.20854 (2005). 
24 Palumbo, M. O. et al. Systemic cancer therapy: achievements and challenges that lie ahead. 
Frontiers in pharmacology 4, 57, doi:10.3389/fphar.2013.00057 (2013). 
25 Boudreaux, J. P. et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. 
Annals of surgery 241, 839-845; discussion 845-836 (2005). 
26 Hodge, J. W., Ardiani, A., Farsaci, B., Kwilas, A. R. & Gameiro, S. R. The tipping point for 
combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule 
inhibitors. Seminars in oncology 39, 323-339, doi:10.1053/j.seminoncol.2012.02.006 (2012). 
27 Hall, J. & Angele, S. Radiation, DNA damage and cancer. Molecular medicine today 5, 157-164 
(1999). 
28 Moding, E. J., Kastan, M. B. & Kirsch, D. G. Strategies for optimizing the response of cancer and 
normal tissues to radiation. Nature reviews. Drug discovery 12, 526-542, doi:10.1038/nrd4003 
(2013). 
  
39 
29 Baskar, R., Lee, K. A., Yeo, R. & Yeoh, K. W. Cancer and radiation therapy: current advances and 
future directions. International journal of medical sciences 9, 193-199, doi:10.7150/ijms.3635 
(2012). 
30 Lee, S. W. et al. Radiation therapy is a treatment to be considered for recurrent epithelial ovarian 
cancer after chemotherapy. Tumori 97, 590-595, doi:10.1700/989.10717 (2011). 
31 Fogarty, G. B. & Hong, A. Radiation therapy for advanced and metastatic melanoma. Journal of 
surgical oncology 109, 370-375, doi:10.1002/jso.23509 (2014). 
32 Grosso, D. A., Hess, R. C. & Weiss, M. A. Immunotherapy in acute myeloid leukemia. Cancer 121, 
2689-2704, doi:10.1002/cncr.29378 (2015). 
33 Chabner, B. A. & Roberts, T. G., Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev 
Cancer 5, 65-72, doi:10.1038/nrc1529 (2005). 
34 Calderon-Montano, J. M., Burgos-Moron, E., Orta, M. L. & Lopez-Lazaro, M. Effect of DNA repair 
deficiencies on the cytotoxicity of drugs used in cancer therapy - a review. Current medicinal 
chemistry 21, 3419-3454 (2014). 
35 Malhotra, V. & Perry, M. C. Classical chemotherapy: mechanisms, toxicities and the therapeutic 
window. Cancer biology & therapy 2, S2-4 (2003). 
36 Povirk, L. F. & Shuker, D. E. DNA damage and mutagenesis induced by nitrogen mustards. 
Mutation research 318, 205-226 (1994). 
37 Damia, G. & D'Incalci, M. Mechanisms of resistance to alkylating agents. Cytotechnology 27, 165-
173, doi:10.1023/a:1008060720608 (1998). 
38 Kaye, S. B. New antimetabolites in cancer chemotherapy and their clinical impact. British journal of 
cancer 78 Suppl 3, 1-7 (1998). 
39 Sinha, B. K. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49, 
11-19 (1995). 
40 Pestell, R. G. & Rizvanov, A. A. Antibiotics for cancer therapy. Oncotarget 6, 2587-2588, 
doi:10.18632/oncotarget.3388 (2015). 
41 Dumontet, C. & Jordan, M. A. Microtubule-binding agents: a dynamic field of cancer therapeutics. 
Nature reviews. Drug discovery 9, 790-803, doi:10.1038/nrd3253 (2010). 
42 Pellegrini, F. & Budman, D. R. Review: tubulin function, action of antitubulin drugs, and new drug 
development. Cancer investigation 23, 264-273 (2005). 
43 Baudino, T. A. Targeted Cancer Therapy: The Next Generation of Cancer Treatment. Current drug 
discovery technologies 12, 3-20 (2015). 
44 Blay, J. Y., Le Cesne, A., Alberti, L. & Ray-Coquart, I. Targeted cancer therapies. Bulletin du cancer 
92, E13-18 (2005). 
45 Sawyers, C. Targeted cancer therapy. Nature 432, 294-297, doi:10.1038/nature03095 (2004). 
46 Kuo, T. & Fisher, G. A. Current status of small-molecule tyrosine kinase inhibitors targeting 
epidermal growth factor receptor in colorectal cancer. Clinical colorectal cancer 5 Suppl 2, S62-70 
(2005). 
47 Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat Rev 
Cancer 9, 28-39, doi:10.1038/nrc2559 (2009). 
48 Perez-Soler, R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung 
cancer. Clinical cancer research : an official journal of the American Association for Cancer 
Research 10, 4238s-4240s, doi:10.1158/1078-0432.ccr-040017 (2004). 
49 Druker, B. J. Imatinib as a paradigm of targeted therapies. Advances in cancer research 91, 1-30, 
doi:10.1016/s0065-230x(04)91001-9 (2004). 
50 Chen, D., Frezza, M., Schmitt, S., Kanwar, J. & Dou, Q. P. Bortezomib as the first proteasome 
inhibitor anticancer drug: current status and future perspectives. Current cancer drug targets 11, 
239-253 (2011). 
51 Wong, S. F. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment 
of colorectal cancer. Clinical therapeutics 27, 684-694, doi:10.1016/j.clinthera.2005.06.003 (2005). 
52 Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting 
multidrug resistance in cancer. Nature reviews. Drug discovery 5, 219-234, doi:10.1038/nrd1984 
(2006). 
53 O'Connor, M. L. et al. Cancer stem cells: A contentious hypothesis now moving forward. Cancer 
letters 344, 180-187, doi:10.1016/j.canlet.2013.11.012 (2014). 
54 Meads, M. B., Gatenby, R. A. & Dalton, W. S. Environment-mediated drug resistance: a major 
contributor to minimal residual disease. Nat Rev Cancer 9, 665-674, doi:10.1038/nrc2714 (2009). 
55 Gottesman, M. M. Mechanisms of cancer drug resistance. Annual review of medicine 53, 615-627, 
doi:10.1146/annurev.med.53.082901.103929 (2002). 
56 Ullah, M. F. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. 
Asian Pacific journal of cancer prevention : APJCP 9, 1-6 (2008). 
57 Hamilton, G. & Rath, B. A short update on cancer chemoresistance. Wiener medizinische 
Wochenschrift (1946) 164, 456-460, doi:10.1007/s10354-014-0311-z (2014). 
 40 
58 Raghunand, N. & Gillies, R. J. pH and drug resistance in tumors. Drug resistance updates : reviews 
and commentaries in antimicrobial and anticancer chemotherapy 3, 39-47, 
doi:10.1054/drup.2000.0119 (2000). 
59 Galmarini, C. M., Mackey, J. R. & Dumontet, C. Nucleoside analogues: mechanisms of drug 
resistance and reversal strategies. Leukemia 15, 875-890 (2001). 
60 Damaraju, V. L. et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance 
to cancer chemotherapy. Oncogene 22, 7524-7536, doi:10.1038/sj.onc.1206952 (2003). 
61 Lin, J. H. & Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. 
Clinical pharmacokinetics 42, 59-98, doi:10.2165/00003088-200342010-00003 (2003). 
62 Tivnan, A. et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug 
response in primary and recurrent glioblastoma multiforme. Frontiers in neuroscience 9, 218, 
doi:10.3389/fnins.2015.00218 (2015). 
63 Gottesman, M. M., Ludwig, J., Xia, D. & Szakacs, G. Defeating drug resistance in cancer. Discovery 
medicine 6, 18-23 (2006). 
64 Nooter, K. & Stoter, G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. 
Pathology, research and practice 192, 768-780, doi:10.1016/s0344-0338(96)80099-9 (1996). 
65 Fodale, V., Pierobon, M., Liotta, L. & Petricoin, E. Mechanism of cell adaptation: when and how do 
cancer cells develop chemoresistance? Cancer journal (Sudbury, Mass.) 17, 89-95, 
doi:10.1097/PPO.0b013e318212dd3d (2011). 
66 Hofmann, W. K. et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) 
treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102, 659-661, 
doi:10.1182/blood-2002-06-1756 (2003). 
67 Inukai, M. et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor 
clone in non-small cell lung cancer. Cancer research 66, 7854-7858, doi:10.1158/0008-5472.can-06-
1951 (2006). 
68 Lai, G. M., Ozols, R. F., Smyth, J. F., Young, R. C. & Hamilton, T. C. Enhanced DNA repair and 
resistance to cisplatin in human ovarian cancer. Biochemical pharmacology 37, 4597-4600 (1988). 
69 Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an 
evolving paradigm. Nat Rev Cancer 13, 714-726, doi:10.1038/nrc3599 (2013). 
70 Sarkaria, J. N. et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. 
Clinical cancer research : an official journal of the American Association for Cancer Research 14, 
2900-2908, doi:10.1158/1078-0432.ccr-07-1719 (2008). 
71 Beier, D., Schulz, J. B. & Beier, C. P. Chemoresistance of glioblastoma cancer stem cells--much 
more complex than expected. Molecular cancer 10, 128, doi:10.1186/1476-4598-10-128 (2011). 
72 Senturker, S., Tschirret-Guth, R., Morrow, J., Levine, R. & Shacter, E. Induction of apoptosis by 
chemotherapeutic drugs without generation of reactive oxygen species. Archives of biochemistry and 
biophysics 397, 262-272, doi:10.1006/abbi.2001.2681 (2002). 
73 Augsten, M., Hagglof, C., Pena, C. & Ostman, A. A digest on the role of the tumor 
microenvironment in gastrointestinal cancers. Cancer microenvironment : official journal of the 
International Cancer Microenvironment Society 3, 167-176, doi:10.1007/s12307-010-0040-9 (2010). 
74 Pietras, K. & Ostman, A. Hallmarks of cancer: interactions with the tumor stroma. Experimental cell 
research 316, 1324-1331, doi:10.1016/j.yexcr.2010.02.045 (2010). 
75 Gatenby, R. A. & Vincent, T. L. An evolutionary model of carcinogenesis. Cancer research 63, 
6212-6220 (2003). 
76 Chiche, J., Brahimi-Horn, M. C. & Pouyssegur, J. Tumour hypoxia induces a metabolic shift causing 
acidosis: a common feature in cancer. Journal of cellular and molecular medicine 14, 771-794, 
doi:10.1111/j.1582-4934.2009.00994.x (2010). 
77 Gatenby, R. A. et al. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast 
cancer. British journal of cancer 97, 646-653, doi:10.1038/sj.bjc.6603922 (2007). 
78 Osawa, T. & Shibuya, M. Targeting cancer cells resistant to hypoxia and nutrient starvation to 
improve anti-angiogeneic therapy. Cell cycle (Georgetown, Tex.) 12, 2519-2520, 
doi:10.4161/cc.25729 (2013). 
79 Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion 
sequencing. The New England journal of medicine 366, 883-892, doi:10.1056/NEJMoa1113205 
(2012). 
80 Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. 
Nature 414, 105-111, doi:10.1038/35102167 (2001). 
81 Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates 
from a primitive hematopoietic cell. Nature medicine 3, 730-737 (1997). 
82 Gilbertson, R. J. & Rich, J. N. Making a tumour's bed: glioblastoma stem cells and the vascular 
niche. Nat Rev Cancer 7, 733-736, doi:10.1038/nrc2246 (2007). 
  
41 
83 Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective 
identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of 
the United States of America 100, 3983-3988, doi:10.1073/pnas.0530291100 (2003). 
84 Lang, S. H., Frame, F. M. & Collins, A. T. Prostate cancer stem cells. The Journal of pathology 217, 
299-306, doi:10.1002/path.2478 (2009). 
85 Li, C., Lee, C. J. & Simeone, D. M. Identification of human pancreatic cancer stem cells. Methods in 
molecular biology (Clifton, N.J.) 568, 161-173, doi:10.1007/978-1-59745-280-9_10 (2009). 
86 Todaro, M., Francipane, M. G., Medema, J. P. & Stassi, G. Colon cancer stem cells: promise of 
targeted therapy. Gastroenterology 138, 2151-2162, doi:10.1053/j.gastro.2009.12.063 (2010). 
87 Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of 
malignant and stem cell traits. Nat Rev Cancer 9, 265-273, doi:10.1038/nrc2620 (2009). 
88 Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. 
Cell 133, 704-715, doi:10.1016/j.cell.2008.03.027 (2008). 
89 Jo, M. et al. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells 
by activation of urokinase receptor-dependent cell signaling. J Biol Chem 284, 22825-22833, 
doi:10.1074/jbc.M109.023960 (2009). 
90 Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. 
Nature reviews. Molecular cell biology 7, 131-142, doi:10.1038/nrm1835 (2006). 
91 Beck, B. & Blanpain, C. Unravelling cancer stem cell potential. Nat Rev Cancer 13, 727-738, 
doi:10.1038/nrc3597 (2013). 
92 Pattabiraman, D. R. & Weinberg, R. A. Tackling the cancer stem cells - what challenges do they 
pose? Nature reviews. Drug discovery 13, 497-512, doi:10.1038/nrd4253 (2014). 
93 Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and 
unresolved questions. Nat Rev Cancer 8, 755-768, doi:10.1038/nrc2499 (2008). 
94 Armulik, A., Abramsson, A. & Betsholtz, C. Endothelial/pericyte interactions. Circulation research 
97, 512-523, doi:10.1161/01.RES.0000182903.16652.d7 (2005). 
95 Bergers, G. & Song, S. The role of pericytes in blood-vessel formation and maintenance. Neuro-
oncology 7, 452-464, doi:10.1215/s1152851705000232 (2005). 
96 Rasanen, K. & Vaheri, A. Activation of fibroblasts in cancer stroma. Experimental cell research 316, 
2713-2722, doi:10.1016/j.yexcr.2010.04.032 (2010). 
97 Giaccia, A. J. & Schipani, E. Role of carcinoma-associated fibroblasts and hypoxia in tumor 
progression. Current topics in microbiology and immunology 345, 31-45, doi:10.1007/82_2010_73 
(2010). 
98 Ahmed, Z. & Bicknell, R. Angiogenic signalling pathways. Methods in molecular biology (Clifton, 
N.J.) 467, 3-24, doi:10.1007/978-1-59745-241-0_1 (2009). 
99 Ruoslahti, E., Bhatia, S. N. & Sailor, M. J. Targeting of drugs and nanoparticles to tumors. J Cell 
Biol 188, 759-768, doi:10.1083/jcb.200910104 (2010). 
100 Coffelt, S. B. et al. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in 
tumors. The American journal of pathology 176, 1564-1576, doi:10.2353/ajpath.2010.090786 
(2010). 
101 Schafer, M. & Werner, S. Cancer as an overhealing wound: an old hypothesis revisited. Nature 
reviews. Molecular cell biology 9, 628-638, doi:10.1038/nrm2455 (2008). 
102 Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-
899, doi:10.1016/j.cell.2010.01.025 (2010). 
103 Peinado, H., Lavotshkin, S. & Lyden, D. The secreted factors responsible for pre-metastatic niche 
formation: old sayings and new thoughts. Seminars in cancer biology 21, 139-146, 
doi:10.1016/j.semcancer.2011.01.002 (2011). 
104 Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674, 
doi:10.1016/j.cell.2011.02.013 (2011). 
105 Lee, J. W., Bae, S. H., Jeong, J. W., Kim, S. H. & Kim, K. W. Hypoxia-inducible factor (HIF-
1)alpha: its protein stability and biological functions. Experimental & molecular medicine 36, 1-12, 
doi:10.1038/emm.2004.1 (2004). 
106 Payen, V. L., Brisson, L., Dewhirst, M. W. & Sonveaux, P. Common responses of tumors and 
wounds to hypoxia. Cancer journal (Sudbury, Mass.) 21, 75-87, 
doi:10.1097/ppo.0000000000000098 (2015). 
107 Lin, C., McGough, R., Aswad, B., Block, J. A. & Terek, R. Hypoxia induces HIF-1alpha and VEGF 
expression in chondrosarcoma cells and chondrocytes. Journal of orthopaedic research : official 
publication of the Orthopaedic Research Society 22, 1175-1181, doi:10.1016/j.orthres.2004.03.002 
(2004). 
108 Feldser, D. et al. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like 
growth factor 2. Cancer research 59, 3915-3918 (1999). 
109 Krishnamachary, B. et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. 
Cancer research 63, 1138-1143 (2003). 
 42 
110 Jones, R. G. & Thompson, C. B. Tumor suppressors and cell metabolism: a recipe for cancer growth. 
Genes & development 23, 537-548, doi:10.1101/gad.1756509 (2009). 
111 Marin-Hernandez, A., Gallardo-Perez, J. C., Ralph, S. J., Rodriguez-Enriquez, S. & Moreno-
Sanchez, R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of 
specific glycolytic isoforms. Mini reviews in medicinal chemistry 9, 1084-1101 (2009). 
112 Greijer, A. E. et al. Up-regulation of gene expression by hypoxia is mediated predominantly by 
hypoxia-inducible factor 1 (HIF-1). The Journal of pathology 206, 291-304, doi:10.1002/path.1778 
(2005). 
113 Riddle, S. R. et al. Hypoxia induces hexokinase II gene expression in human lung cell line A549. 
American journal of physiology. Lung cellular and molecular physiology 278, L407-416 (2000). 
114 Masson, N. & Ratcliffe, P. J. Hypoxia signaling pathways in cancer metabolism: the importance of 
co-selecting interconnected physiological pathways. Cancer & metabolism 2, 3, doi:10.1186/2049-
3002-2-3 (2014). 
115 Warburg, O., Wind, F. & Negelein, E. THE METABOLISM OF TUMORS IN THE BODY. The 
Journal of general physiology 8, 519-530 (1927). 
116 Adekola, K., Rosen, S. T. & Shanmugam, M. Glucose transporters in cancer metabolism. Current 
opinion in oncology 24, 650-654, doi:10.1097/CCO.0b013e328356da72 (2012). 
117 Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not 
anticipate. Cancer cell 21, 297-308, doi:10.1016/j.ccr.2012.02.014 (2012). 
118 Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the 
metabolic requirements of cell proliferation. Science (New York, N.Y.) 324, 1029-1033, 
doi:10.1126/science.1160809 (2009). 
119 Yeung, S. J., Pan, J. & Lee, M. H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the 
seventh hallmark of cancer. Cellular and molecular life sciences : CMLS 65, 3981-3999, 
doi:10.1007/s00018-008-8224-x (2008). 
120 Schwartzenberg-Bar-Yoseph, F., Armoni, M. & Karnieli, E. The tumor suppressor p53 down-
regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer research 64, 2627-2633 
(2004). 
121 Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120, 
doi:10.1016/j.cell.2006.05.036 (2006). 
122 Liu, W. et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative 
and metabolic responses regulated by oncogenic transcription factor c-MYC. Proceedings of the 
National Academy of Sciences of the United States of America 109, 8983-8988, 
doi:10.1073/pnas.1203244109 (2012). 
123 Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and 
glutamine metabolism. Nature 458, 762-765, doi:10.1038/nature07823 (2009). 
124 Morrish, F. & Hockenbery, D. MYC and mitochondrial biogenesis. Cold Spring Harbor perspectives 
in medicine 4, doi:10.1101/cshperspect.a014225 (2014). 
125 DeBerardinis, R. J. Is cancer a disease of abnormal cellular metabolism? New angles on an old idea. 
Genetics in medicine : official journal of the American College of Medical Genetics 10, 767-777, 
doi:10.1097/GIM.0b013e31818b0d9b (2008). 
126 Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4, 
891-899, doi:10.1038/nrc1478 (2004). 
127 Sonveaux, P. et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. 
J Clin Invest 118, 3930-3942, doi:10.1172/jci36843 (2008). 
128 Payen, V. L., Porporato, P. E., Baselet, B. & Sonveaux, P. Metabolic changes associated with tumor 
metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cellular and molecular 
life sciences : CMLS, doi:10.1007/s00018-015-2098-5 (2015). 
129 Pavlides, S. et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and 
the tumor stroma. Cell cycle (Georgetown, Tex.) 8, 3984-4001 (2009). 
130 Dhup, S., Dadhich, R. K., Porporato, P. E. & Sonveaux, P. Multiple biological activities of lactic 
acid in cancer: influences on tumor growth, angiogenesis and metastasis. Current pharmaceutical 
design 18, 1319-1330 (2012). 
131 Gillies, R. J., Raghunand, N., Karczmar, G. S. & Bhujwalla, Z. M. MRI of the tumor 
microenvironment. Journal of magnetic resonance imaging : JMRI 16, 430-450, 
doi:10.1002/jmri.10181 (2002). 
132 De Saedeleer, C. J. et al. Glucose deprivation increases monocarboxylate transporter 1 (MCT1) 
expression and MCT1-dependent tumor cell migration. Oncogene 33, 4060-4068, 
doi:10.1038/onc.2013.454 (2014). 
133 Masereel, B., Pochet, L. & Laeckmann, D. An overview of inhibitors of Na(+)/H(+) exchanger. 
European journal of medicinal chemistry 38, 547-554 (2003). 
134 Toei, M., Saum, R. & Forgac, M. Regulation and isoform function of the V-ATPases. Biochemistry 
49, 4715-4723, doi:10.1021/bi100397s (2010). 
  
43 
135 Supuran, C. T. Carbonic anhydrases--an overview. Current pharmaceutical design 14, 603-614 
(2008). 
136 Neri, D. & Supuran, C. T. Interfering with pH regulation in tumours as a therapeutic strategy. Nature 
reviews. Drug discovery 10, 767-777, doi:10.1038/nrd3554 (2011). 
137 De Milito, A. & Fais, S. Tumor acidity, chemoresistance and proton pump inhibitors. Future 
oncology (London, England) 1, 779-786, doi:10.2217/14796694.1.6.779 (2005). 
138 Gatenby, R. A., Gawlinski, E. T., Gmitro, A. F., Kaylor, B. & Gillies, R. J. Acid-mediated tumor 
invasion: a multidisciplinary study. Cancer research 66, 5216-5223, doi:10.1158/0008-5472.can-05-
4193 (2006). 
139 Rofstad, E. K., Mathiesen, B., Kindem, K. & Galappathi, K. Acidic extracellular pH promotes 
experimental metastasis of human melanoma cells in athymic nude mice. Cancer research 66, 6699-
6707, doi:10.1158/0008-5472.can-06-0983 (2006). 
140 Shi, Q. et al. Regulation of vascular endothelial growth factor expression by acidosis in human 
cancer cells. Oncogene 20, 3751-3756, doi:10.1038/sj.onc.1204500 (2001). 
141 Xu, L. & Fidler, I. J. Acidic pH-induced elevation in interleukin 8 expression by human ovarian 
carcinoma cells. Cancer research 60, 4610-4616 (2000). 
142 Yuan, J., Narayanan, L., Rockwell, S. & Glazer, P. M. Diminished DNA repair and elevated 
mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer research 60, 4372-4376 
(2000). 
143 Riemann, A. et al. Acidosis differently modulates the inflammatory program in monocytes and 
macrophages. Biochimica et biophysica acta 1862, 72-81, doi:10.1016/j.bbadis.2015.10.017 (2016). 
144 Calcinotto, A. et al. Modulation of microenvironment acidity reverses anergy in human and murine 
tumor-infiltrating T lymphocytes. Cancer research 72, 2746-2756, doi:10.1158/0008-5472.can-11-
1272 (2012). 
145 Mahoney, B. P., Raghunand, N., Baggett, B. & Gillies, R. J. Tumor acidity, ion trapping and 
chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. 
Biochemical pharmacology 66, 1207-1218 (2003). 
146 Wojtkowiak, J. W., Verduzco, D., Schramm, K. J. & Gillies, R. J. Drug resistance and cellular 
adaptation to tumor acidic pH microenvironment. Molecular pharmaceutics 8, 2032-2038, 
doi:10.1021/mp200292c (2011). 
147 Marino, M. L. et al. Autophagy is a protective mechanism for human melanoma cells under acidic 
stress. J Biol Chem 287, 30664-30676, doi:10.1074/jbc.M112.339127 (2012). 
148 Wojtkowiak, J. W. et al. Chronic autophagy is a cellular adaptation to tumor acidic pH 
microenvironments. Cancer research 72, 3938-3947, doi:10.1158/0008-5472.can-11-3881 (2012). 
149 Kong, J. et al. Autophagy levels are elevated in barrett's esophagus and promote cell survival from 
acid and oxidative stress. Molecular carcinogenesis, doi:10.1002/mc.22406 (2015). 
150 Al-Awqati, Q. One hundred years of membrane permeability: does Overton still rule? Nature cell 
biology 1, E201-202, doi:10.1038/70230 (1999). 
151 De Milito, A. & Fais, S. Proton pump inhibitors may reduce tumour resistance. Expert opinion on 
pharmacotherapy 6, 1049-1054, doi:10.1517/14656566.6.7.1049 (2005). 
152 Gatenby, R. A. & Gillies, R. J. Glycolysis in cancer: a potential target for therapy. The international 
journal of biochemistry & cell biology 39, 1358-1366, doi:10.1016/j.biocel.2007.03.021 (2007). 
153 Lin, H. J. Role of proton pump inhibitors in the management of peptic ulcer bleeding. World journal 
of gastrointestinal pharmacology and therapeutics 1, 51-53, doi:10.4292/wjgpt.v1.i2.51 (2010). 
154 Luciani, F. et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to 
cytotoxic drugs. Journal of the National Cancer Institute 96, 1702-1713, doi:10.1093/jnci/djh305 
(2004). 
155 De Milito, A. et al. pH-dependent antitumor activity of proton pump inhibitors against human 
melanoma is mediated by inhibition of tumor acidity. International journal of cancer 127, 207-219, 
doi:10.1002/ijc.25009 (2010). 
156 De Milito, A. et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a 
caspase-independent mechanism involving reactive oxygen species. Cancer research 67, 5408-5417, 
doi:10.1158/0008-5472.can-06-4095 (2007). 
157 Wang, B. Y. et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of 
chemotherapy in metastatic breast cancer. Journal of experimental & clinical cancer research : CR 
34, 85, doi:10.1186/s13046-015-0194-x (2015). 
158 Owa, T. et al. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. 
Journal of medicinal chemistry 42, 3789-3799 (1999). 
159 Ozawa, Y. et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in 
vivo. European journal of cancer (Oxford, England : 1990) 37, 2275-2282 (2001). 
160 Supuran, C. T. Indisulam: an anticancer sulfonamide in clinical development. Expert opinion on 
investigational drugs 12, 283-287, doi:10.1517/13543784.12.2.283 (2003). 
 44 
161 Supuran, C. T. How many carbonic anhydrase inhibition mechanisms exist? Journal of enzyme 
inhibition and medicinal chemistry 31, 345-360, doi:10.3109/14756366.2015.1122001 (2016). 
162 Robey, I. F. et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer 
research 69, 2260-2268, doi:10.1158/0008-5472.can-07-5575 (2009). 
163 Mizushima, N. & Komatsu, M. Autophagy: renovation of cells and tissues. Cell 147, 728-741, 
doi:10.1016/j.cell.2011.10.026 (2011). 
164 Kumar, A., Singh, U. K. & Chaudhary, A. Targeting autophagy to overcome drug resistance in 
cancer therapy. Future medicinal chemistry 7, 1535-1542, doi:10.4155/fmc.15.88 (2015). 
165 Shen, M., Schmitt, S., Buac, D. & Dou, Q. P. Targeting the ubiquitin-proteasome system for cancer 
therapy. Expert opinion on therapeutic targets 17, 1091-1108, doi:10.1517/14728222.2013.815728 
(2013). 
166 Yang, Z. & Klionsky, D. J. Eaten alive: a history of macroautophagy. Nature cell biology 12, 814-
822, doi:10.1038/ncb0910-814 (2010). 
167 Appelmans, F., Wattiaux, R. & De Duve, C. Tissue fractionation studies. 5. The association of acid 
phosphatase with a special class of cytoplasmic granules in rat liver. The Biochemical journal 59, 
438-445 (1955). 
168 Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy 
(3rd edition). Autophagy 12, 1-222, doi:10.1080/15548627.2015.1100356 (2016). 
169 Li, W. W., Li, J. & Bao, J. K. Microautophagy: lesser-known self-eating. Cellular and molecular life 
sciences : CMLS 69, 1125-1136, doi:10.1007/s00018-011-0865-5 (2012). 
170 Feng, Y., He, D., Yao, Z. & Klionsky, D. J. The machinery of macroautophagy. Cell research 24, 
24-41, doi:10.1038/cr.2013.168 (2014). 
171 Dice, J. F. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends in 
biochemical sciences 15, 305-309 (1990). 
172 Cuervo, A. M. & Wong, E. Chaperone-mediated autophagy: roles in disease and aging. Cell research 
24, 92-104, doi:10.1038/cr.2013.153 (2014). 
173 Svenning, S. & Johansen, T. Selective autophagy. Essays in biochemistry 55, 79-92, 
doi:10.1042/bse0550079 (2013). 
174 Klionsky, D. J. & Emr, S. D. Autophagy as a regulated pathway of cellular degradation. Science 
(New York, N.Y.) 290, 1717-1721 (2000). 
175 Glick, D., Barth, S. & Macleod, K. F. Autophagy: cellular and molecular mechanisms. The Journal 
of pathology 221, 3-12, doi:10.1002/path.2697 (2010). 
176 Maycotte, P. & Thorburn, A. Autophagy and cancer therapy. Cancer biology & therapy 11, 127-137 
(2011). 
177 King, J. S., Veltman, D. M. & Insall, R. H. The induction of autophagy by mechanical stress. 
Autophagy 7, 1490-1499 (2011). 
178 Nakatogawa, H., Suzuki, K., Kamada, Y. & Ohsumi, Y. Dynamics and diversity in autophagy 
mechanisms: lessons from yeast. Nature reviews. Molecular cell biology 10, 458-467, 
doi:10.1038/nrm2708 (2009). 
179 Melendez, A. & Levine, B. Autophagy in C. elegans. WormBook : the online review of C. elegans 
biology, 1-26, doi:10.1895/wormbook.1.147.1 (2009). 
180 Chan, E. Y. Regulation and function of uncoordinated-51 like kinase proteins. Antioxidants & redox 
signaling 17, 775-785, doi:10.1089/ars.2011.4396 (2012). 
181 Chen, Y. & Klionsky, D. J. The regulation of autophagy - unanswered questions. Journal of cell 
science 124, 161-170, doi:10.1242/jcs.064576 (2011). 
182 He, C., Baba, M. & Klionsky, D. J. Double duty of Atg9 self-association in autophagosome 
biogenesis. Autophagy 5, 385-387 (2009). 
183 Klionsky, D. J. & Codogno, P. The mechanism and physiological function of macroautophagy. 
Journal of innate immunity 5, 427-433, doi:10.1159/000351979 (2013). 
184 Takahashi, Y. et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and 
tumorigenesis. Nature cell biology 9, 1142-1151, doi:10.1038/ncb1634 (2007). 
185 Marquez, R. T. & Xu, L. Bcl-2:Beclin 1 complex: multiple, mechanisms regulating 
autophagy/apoptosis toggle switch. American journal of cancer research 2, 214-221 (2012). 
186 Tanida, I., Ueno, T. & Kominami, E. LC3 conjugation system in mammalian autophagy. The 
international journal of biochemistry & cell biology 36, 2503-2518, 
doi:10.1016/j.biocel.2004.05.009 (2004). 
187 Tanida, I., Ueno, T. & Kominami, E. LC3 and Autophagy. Methods in molecular biology (Clifton, 
N.J.) 445, 77-88, doi:10.1007/978-1-59745-157-4_4 (2008). 
188 Bjorkoy, G. et al. Monitoring autophagic degradation of p62/SQSTM1. Methods in enzymology 452, 
181-197, doi:10.1016/s0076-6879(08)03612-4 (2009). 
189 Donohue, E., Balgi, A. D., Komatsu, M. & Roberge, M. Induction of Covalently Crosslinked p62 
Oligomers with Reduced Binding to Polyubiquitinated Proteins by the Autophagy Inhibitor 
Verteporfin. PloS one 9, e114964, doi:10.1371/journal.pone.0114964 (2014). 
  
45 
190 Majeski, A. E. & Dice, J. F. Mechanisms of chaperone-mediated autophagy. The international 
journal of biochemistry & cell biology 36, 2435-2444, doi:10.1016/j.biocel.2004.02.013 (2004). 
191 McEwan, D. G. et al. PLEKHM1 regulates autophagosome-lysosome fusion through HOPS complex 
and LC3/GABARAP proteins. Molecular cell 57, 39-54, doi:10.1016/j.molcel.2014.11.006 (2015). 
192 Luzio, J. P., Pryor, P. R. & Bright, N. A. Lysosomes: fusion and function. Nature reviews. Molecular 
cell biology 8, 622-632, doi:10.1038/nrm2217 (2007). 
193 Levine, B. & Kroemer, G. Autophagy in the pathogenesis of disease. Cell 132, 27-42, 
doi:10.1016/j.cell.2007.12.018 (2008). 
194 Martin, D. D., Ladha, S., Ehrnhoefer, D. E. & Hayden, M. R. Autophagy in Huntington disease and 
huntingtin in autophagy. Trends in neurosciences 38, 26-35, doi:10.1016/j.tins.2014.09.003 (2015). 
195 Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M. & Klionsky, D. J. The role of autophagy in 
Parkinson's disease. Cold Spring Harbor perspectives in medicine 2, a009357, 
doi:10.1101/cshperspect.a009357 (2012). 
196 Frake, R. A., Ricketts, T., Menzies, F. M. & Rubinsztein, D. C. Autophagy and neurodegeneration. J 
Clin Invest 125, 65-74, doi:10.1172/jci73944 (2015). 
197 White, E. & DiPaola, R. S. The double-edged sword of autophagy modulation in cancer. Clinical 
cancer research : an official journal of the American Association for Cancer Research 15, 5308-
5316, doi:10.1158/1078-0432.ccr-07-5023 (2009). 
198 Maiuri, M. C. et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell death and 
differentiation 16, 87-93, doi:10.1038/cdd.2008.131 (2009). 
199 Mathew, R., Karantza-Wadsworth, V. & White, E. Role of autophagy in cancer. Nat Rev Cancer 7, 
961-967, doi:10.1038/nrc2254 (2007). 
200 Liang, C. et al. Autophagic and tumour suppressor activity of a novel Beclin1-binding protein 
UVRAG. Nature cell biology 8, 688-699, doi:10.1038/ncb1426 (2006). 
201 Jin, S. Autophagy, mitochondrial quality control, and oncogenesis. Autophagy 2, 80-84 (2006). 
202 Takamura, A. et al. Autophagy-deficient mice develop multiple liver tumors. Genes & development 
25, 795-800, doi:10.1101/gad.2016211 (2011). 
203 Gillies, R. J., Robey, I. & Gatenby, R. A. Causes and consequences of increased glucose metabolism 
of cancers. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 49 Suppl 
2, 24s-42s, doi:10.2967/jnumed.107.047258 (2008). 
204 Pursiheimo, J. P., Rantanen, K., Heikkinen, P. T., Johansen, T. & Jaakkola, P. M. Hypoxia-activated 
autophagy accelerates degradation of SQSTM1/p62. Oncogene 28, 334-344, 
doi:10.1038/onc.2008.392 (2009). 
205 Wu, H. M., Jiang, Z. F., Ding, P. S., Shao, L. J. & Liu, R. Y. Hypoxia-induced autophagy mediates 
cisplatin resistance in lung cancer cells. Scientific reports 5, 12291, doi:10.1038/srep12291 (2015). 
206 Papandreou, I., Lim, A. L., Laderoute, K. & Denko, N. C. Hypoxia signals autophagy in tumor cells 
via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell death and differentiation 15, 
1572-1581, doi:10.1038/cdd.2008.84 (2008). 
207 Bellot, G. et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction 
of BNIP3 and BNIP3L via their BH3 domains. Molecular and cellular biology 29, 2570-2581, 
doi:10.1128/mcb.00166-09 (2009). 
208 Li, L., Chen, Y. & Gibson, S. B. Starvation-induced autophagy is regulated by mitochondrial 
reactive oxygen species leading to AMPK activation. Cellular signalling 25, 50-65, 
doi:10.1016/j.cellsig.2012.09.020 (2013). 
209 Sivridis, E. et al. Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic 
survival pattern for beclin-1. Melanoma research 21, 188-195, 
doi:10.1097/CMR.0b013e328346612c (2011). 
210 Giatromanolaki, A. et al. Prognostic relevance of light chain 3 (LC3A) autophagy patterns in 
colorectal adenocarcinomas. Journal of clinical pathology 63, 867-872, 
doi:10.1136/jcp.2010.079525 (2010). 
211 Abedin, M. J., Wang, D., McDonnell, M. A., Lehmann, U. & Kelekar, A. Autophagy delays 
apoptotic death in breast cancer cells following DNA damage. Cell death and differentiation 14, 500-
510, doi:10.1038/sj.cdd.4402039 (2007). 
212 Yang, Z. J., Chee, C. E., Huang, S. & Sinicrope, F. A. The role of autophagy in cancer: therapeutic 
implications. Molecular cancer therapeutics 10, 1533-1541, doi:10.1158/1535-7163.mct-11-0047 
(2011). 
213 Pan, X. et al. Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS 
formation in human non-small cell lung cancer A549 cells. PloS one 8, e56679, 
doi:10.1371/journal.pone.0056679 (2013). 
214 Li, J. et al. Inhibition of autophagy by 3-MA enhances the effect of 5-FU-induced apoptosis in colon 
cancer cells. Annals of surgical oncology 16, 761-771, doi:10.1245/s10434-008-0260-0 (2009). 
 46 
215 Lamberti, M. et al. Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy 
inhibition: clinical and occupational implications. International journal of oncology 46, 1893-1900, 
doi:10.3892/ijo.2015.2904 (2015). 
216 Wang, C., Hu, Q. & Shen, H. M. Pharmacological inhibitors of autophagy as novel cancer 
therapeutic agents. Pharmacological research 105, 164-175, doi:10.1016/j.phrs.2016.01.028 (2016). 
217 Amaravadi, R. K. et al. Principles and current strategies for targeting autophagy for cancer treatment. 
Clinical cancer research : an official journal of the American Association for Cancer Research 17, 
654-666, doi:10.1158/1078-0432.ccr-10-2634 (2011). 
218 Vlahos, C. J., Matter, W. F., Hui, K. Y. & Brown, R. F. A specific inhibitor of phosphatidylinositol 
3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269, 5241-
5248 (1994). 
219 Powis, G. et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. 
Cancer research 54, 2419-2423 (1994). 
220 Blommaart, E. F., Krause, U., Schellens, J. P., Vreeling-Sindelarova, H. & Meijer, A. J. The 
phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat 
hepatocytes. European journal of biochemistry / FEBS 243, 240-246 (1997). 
221 Akin, D. et al. A novel ATG4B antagonist inhibits autophagy and has a negative impact on 
osteosarcoma tumors. Autophagy 10, 2021-2035, doi:10.4161/auto.32229 (2014). 
222 Egan, D. F. et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of 
ULK1 Substrates. Molecular cell 59, 285-297, doi:10.1016/j.molcel.2015.05.031 (2015). 
223 Dowdle, W. E. et al. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in 
ferritin degradation and iron homeostasis in vivo. Nature cell biology 16, 1069-1079, 
doi:10.1038/ncb3053 (2014). 
224 Pasquier, B. SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with 
MTOR inhibition in tumor cells. Autophagy 11, 725-726, doi:10.1080/15548627.2015.1033601 
(2015). 
225 Li, M. et al. Suppression of lysosome function induces autophagy via a feedback down-regulation of 
MTOR complex 1 (MTORC1) activity. J Biol Chem 288, 35769-35780, 
doi:10.1074/jbc.M113.511212 (2013). 
226 Tanida, I., Minematsu-Ikeguchi, N., Ueno, T. & Kominami, E. Lysosomal turnover, but not a 
cellular level, of endogenous LC3 is a marker for autophagy. Autophagy 1, 84-91 (2005). 
227 Amaravadi, R. K. & Winkler, J. D. Lys05: a new lysosomal autophagy inhibitor. Autophagy 8, 1383-
1384, doi:10.4161/auto.20958 (2012). 
228 Bourne, S. A., De Villiers, K. & Egan, T. J. Three 4-aminoquinolines of antimalarial interest. Acta 
crystallographica. Section C, Crystal structure communications 62, o53-57, 
doi:10.1107/s0108270105041235 (2006). 
229 Sullivan, D. J., Jr., Gluzman, I. Y., Russell, D. G. & Goldberg, D. E. On the molecular mechanism of 
chloroquine's antimalarial action. Proceedings of the National Academy of Sciences of the United 
States of America 93, 11865-11870 (1996). 
230 Freedman, A. & Steinberg, V. L. Chloroquine in rheumatoid arthritis; a double blindfold trial of 
treatment for one year. Annals of the rheumatic diseases 19, 243-250 (1960). 
231 Wozniacka, A., Lesiak, A., Narbutt, J., McCauliffe, D. P. & Sysa-Jedrzejowska, A. Chloroquine 
treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. 
Lupus 15, 268-275 (2006). 
232 Solomon, V. R. & Lee, H. Chloroquine and its analogs: a new promise of an old drug for effective 
and safe cancer therapies. European journal of pharmacology 625, 220-233, 
doi:10.1016/j.ejphar.2009.06.063 (2009). 
233 Pascolo, S. Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. 
European journal of pharmacology 771, 139-144, doi:10.1016/j.ejphar.2015.12.017 (2016). 
234 Zhao, X. G. et al. Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal 
carcinoma in xenograft mice. PloS one 10, e0126147, doi:10.1371/journal.pone.0126147 (2015). 
235 Warhurst, D. C., Steele, J. C., Adagu, I. S., Craig, J. C. & Cullander, C. Hydroxychloroquine is much 
less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with 
its physicochemical properties. The Journal of antimicrobial chemotherapy 52, 188-193, 
doi:10.1093/jac/dkg319 (2003). 
236 Balic, A. et al. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and 
hedgehog signaling. Molecular cancer therapeutics 13, 1758-1771, doi:10.1158/1535-7163.mct-13-
0948 (2014). 
237 Taylor, W. R. & White, N. J. Antimalarial drug toxicity: a review. Drug safety 27, 25-61 (2004). 
238 Jiang, P. D. et al. Antitumor and antimetastatic activities of chloroquine diphosphate in a murine 
model of breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 64, 
609-614, doi:10.1016/j.biopha.2010.06.004 (2010). 
  
47 
239 Amaravadi, R. K. et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced 
model of lymphoma. J Clin Invest 117, 326-336, doi:10.1172/jci28833 (2007). 
240 Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A. & O'Dwyer, P. J. Autophagy inhibition 
sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy. Clinical cancer research : an 
official journal of the American Association for Cancer Research 19, 2995-3007, doi:10.1158/1078-
0432.ccr-12-1542 (2013). 
241 Boya, P. et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated 
apoptosis induced by hydroxychloroquine. Oncogene 22, 3927-3936, doi:10.1038/sj.onc.1206622 
(2003). 
242 Jiang, P. D. et al. Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by 
chloroquine in human breast cancer cell line Bcap-37. Cellular physiology and biochemistry : 
international journal of experimental cellular physiology, biochemistry, and pharmacology 22, 431-
440, doi:10.1159/000185488 (2008). 
243 Choi, D. S. et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and 
DNMT1. Stem cells (Dayton, Ohio) 32, 2309-2323, doi:10.1002/stem.1746 (2014). 
244 Sternglanz, H., Yielding, K. L. & Pruitt, K. M. Nuclear magnetic resonance studies of the interaction 
of chloroquine diphosphate with adenosine 5'-phosphate and other nucleotides. Mol Pharmacol 5, 
376-381 (1969). 
245 Field, R. C., Gibson, B. R., Holbrook, D. J., Jr. & McCall, B. M. Inhibition of precursor 
incorporation into nucleic acids of mammalian tissues by antimalarial aminoquinolines. British 
journal of pharmacology 62, 159-164 (1978). 
246 Rossi, T. et al. Effects of anti-malarial drugs on MCF-7 and Vero cell replication. Anticancer 
research 27, 2555-2559 (2007). 
247 Vezmar, M. & Georges, E. Direct binding of chloroquine to the multidrug resistance protein (MRP): 
possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochemical 
pharmacology 56, 733-742 (1998). 
248 Vezmar, M. & Georges, E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based 
drugs. Biochemical pharmacology 59, 1245-1252 (2000). 
249 Ratikan, J. A., Sayre, J. W. & Schaue, D. Chloroquine engages the immune system to eradicate 
irradiated breast tumors in mice. International journal of radiation oncology, biology, physics 87, 
761-768, doi:10.1016/j.ijrobp.2013.07.024 (2013). 
250 van den Borne, B. E., Dijkmans, B. A., de Rooij, H. H., le Cessie, S. & Verweij, C. L. Chloroquine 
and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-
gamma production by peripheral blood mononuclear cells. The Journal of rheumatology 24, 55-60 
(1997). 
251 Mirzoeva, O. K. et al. Autophagy suppression promotes apoptotic cell death in response to inhibition 
of the PI3K-mTOR pathway in pancreatic adenocarcinoma. Journal of molecular medicine (Berlin, 
Germany) 89, 877-889, doi:10.1007/s00109-011-0774-y (2011). 
252 Bristol, M. L. et al. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do 
the preclinical data support this therapeutic strategy? The Journal of pharmacology and experimental 
therapeutics 344, 544-552, doi:10.1124/jpet.112.199802 (2013). 
253 Yang, A. & Kimmelman, A. C. Inhibition of autophagy attenuates pancreatic cancer growth 
independent of TP53/TRP53 status. Autophagy 10, 1683-1684, doi:10.4161/auto.29961 (2014). 
254 Poklepovic, A. & Gewirtz, D. A. Outcome of early clinical trials of the combination of 
hydroxychloroquine with chemotherapy in cancer. Autophagy 10, 1478-1480, 
doi:10.4161/auto.29428 (2014). 
255 Mahalingam, D. et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, 
pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the 
HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 10, 1403-1414, 
doi:10.4161/auto.29231 (2014). 
256 Garber, K. Inducing indigestion: companies embrace autophagy inhibitors. Journal of the National 
Cancer Institute 103, 708-710, doi:10.1093/jnci/djr168 (2011). 
257 Chapman, H. D., Jeffers, T. K. & Williams, R. B. Forty years of monensin for the control of 
coccidiosis in poultry. Poultry science 89, 1788-1801, doi:10.3382/ps.2010-00931 (2010). 
258 Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput 
screening. Cell 138, 645-659, doi:10.1016/j.cell.2009.06.034 (2009). 
259 Fuchs, D., Daniel, V., Sadeghi, M., Opelz, G. & Naujokat, C. Salinomycin overcomes ABC 
transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a 
cells. Biochemical and biophysical research communications 394, 1098-1104, 
doi:10.1016/j.bbrc.2010.03.138 (2010). 
260 Lu, D. et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic 
lymphocytic leukemia cells. Proceedings of the National Academy of Sciences of the United States of 
America 108, 13253-13257, doi:10.1073/pnas.1110431108 (2011). 
 48 
261 Wang, F. et al. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular 
carcinoma cells in vitro and in vivo. PloS one 7, e50638, doi:10.1371/journal.pone.0050638 (2012). 
262 Dong, T. T. et al. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases 
malignant traits in colorectal cancer lines. Annals of surgical oncology 18, 1797-1804, 
doi:10.1245/s10434-011-1561-2 (2011). 
263 Kim, J. H. et al. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide 
treatment by increasing DNA damage and reducing p21 protein. British journal of pharmacology 
162, 773-784, doi:10.1111/j.1476-5381.2010.01089.x (2011). 
264 Huczynski, A. Salinomycin: a new cancer drug candidate. Chemical biology & drug design 79, 235-
238, doi:10.1111/j.1747-0285.2011.01287.x (2012). 
265 Yue, W. et al. Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor 
cells interferes with their maintenance. Autophagy 9, 714-729, doi:10.4161/auto.23997 (2013). 
266 Klose, J. et al. Inhibition of autophagic flux by salinomycin results in anti-cancer effect in 
hepatocellular carcinoma cells. PloS one 9, e95970, doi:10.1371/journal.pone.0095970 (2014). 
267 Gong, C. et al. Beclin 1 and autophagy are required for the tumorigenicity of breast cancer stem-
like/progenitor cells. Oncogene 32, 2261-2272, 2272e.2261-2211, doi:10.1038/onc.2012.252 (2013). 
268 Wolf, J. et al. A mammosphere formation RNAi screen reveals that ATG4A promotes a breast 
cancer stem-like phenotype. Breast cancer research : BCR 15, R109, doi:10.1186/bcr3576 (2013). 
269 Verdoodt, B. et al. Salinomycin induces autophagy in colon and breast cancer cells with concomitant 
generation of reactive oxygen species. PloS one 7, e44132, doi:10.1371/journal.pone.0044132 
(2012). 
270 Li, T. et al. Salinomycin induces cell death with autophagy through activation of endoplasmic 
reticulum stress in human cancer cells. Autophagy 9, 1057-1068, doi:10.4161/auto.24632 (2013). 
271 Jangamreddy, J. R. et al. Salinomycin induces activation of autophagy, mitophagy and affects 
mitochondrial polarity: differences between primary and cancer cells. Biochimica et biophysica acta 
1833, 2057-2069, doi:10.1016/j.bbamcr.2013.04.011 (2013). 
272 Boehmerle, W. & Endres, M. Salinomycin induces calpain and cytochrome c-mediated neuronal cell 
death. Cell death & disease 2, e168, doi:10.1038/cddis.2011.46 (2011). 
273 Naujokat, C. & Steinhart, R. Salinomycin as a drug for targeting human cancer stem cells. Journal of 
biomedicine & biotechnology 2012, 950658, doi:10.1155/2012/950658 (2012). 
274 Antoszczak, M. et al. Synthesis, anticancer and antibacterial activity of salinomycin N-benzyl 
amides. Molecules (Basel, Switzerland) 19, 19435-19459, doi:10.3390/molecules191219435 (2014). 
275 Borgstrom, B. et al. Synthetic modification of salinomycin: selective O-acylation and biological 
evaluation. Chemical communications (Cambridge, England) 49, 9944-9946, 
doi:10.1039/c3cc45983g (2013). 
276 Huang, X. et al. Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin 
analogs. BMC cancer 16, 145, doi:10.1186/s12885-016-2142-3 (2016). 
277 Wilkinson, K. D. The discovery of ubiquitin-dependent proteolysis. Proceedings of the National 
Academy of Sciences of the United States of America 102, 15280-15282, 
doi:10.1073/pnas.0504842102 (2005). 
278 Hershko, A. & Ciechanover, A. The ubiquitin system. Annual review of biochemistry 67, 425-479, 
doi:10.1146/annurev.biochem.67.1.425 (1998). 
279 Ciechanover, A., Orian, A. & Schwartz, A. L. The ubiquitin-mediated proteolytic pathway: mode of 
action and clinical implications. Journal of cellular biochemistry. Supplement 34, 40-51 (2000). 
280 Ciechanover, A. & Kwon, Y. T. Degradation of misfolded proteins in neurodegenerative diseases: 
therapeutic targets and strategies. Experimental & molecular medicine 47, e147, 
doi:10.1038/emm.2014.117 (2015). 
281 Adams, J. The proteasome: structure, function, and role in the cell. Cancer treatment reviews 29 
Suppl 1, 3-9 (2003). 
282 Farshi, P. et al. Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert opinion on 
therapeutic patents 25, 1191-1208, doi:10.1517/13543776.2015.1056737 (2015). 
283 Haglund, K. & Dikic, I. Ubiquitylation and cell signaling. The EMBO journal 24, 3353-3359, 
doi:10.1038/sj.emboj.7600808 (2005). 
284 Jacobson, A. D. et al. The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by 
the 26 s proteasome. J Biol Chem 284, 35485-35494, doi:10.1074/jbc.M109.052928 (2009). 
285 Ferreira, J. V., Soares, A. R., Ramalho, J. S., Pereira, P. & Girao, H. K63 linked ubiquitin chain 
formation is a signal for HIF1A degradation by Chaperone-Mediated Autophagy. Scientific reports 
5, 10210, doi:10.1038/srep10210 (2015). 
286 Noguchi, M., Hirata, N. & Suizu, F. The links between AKT and two intracellular proteolytic 
cascades: ubiquitination and autophagy. Biochimica et biophysica acta 1846, 342-352, 
doi:10.1016/j.bbcan.2014.07.013 (2014). 
287 Orlowski, R. Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell death and 
differentiation 6, 303-313, doi:10.1038/sj.cdd.4400505 (1999). 
  
49 
288 Shang, F., Nowell, T. R., Jr. & Taylor, A. Removal of oxidatively damaged proteins from lens cells 
by the ubiquitin-proteasome pathway. Experimental eye research 73, 229-238, 
doi:10.1006/exer.2001.1029 (2001). 
289 Devoy, A., Soane, T., Welchman, R. & Mayer, R. J. The ubiquitin-proteasome system and cancer. 
Essays in biochemistry 41, 187-203, doi:10.1042/eb0410187 (2005). 
290 Alley, M. C. et al. Feasibility of drug screening with panels of human tumor cell lines using a 
microculture tetrazolium assay. Cancer research 48, 589-601 (1988). 
291 Suggitt, M. & Bibby, M. C. 50 years of preclinical anticancer drug screening: empirical to target-
driven approaches. Clinical cancer research : an official journal of the American Association for 
Cancer Research 11, 971-981 (2005). 
292 Balis, F. M. Evolution of anticancer drug discovery and the role of cell-based screening. Journal of 
the National Cancer Institute 94, 78-79 (2002). 
293 Druker, B. J. & Lydon, N. B. Lessons learned from the development of an abl tyrosine kinase 
inhibitor for chronic myelogenous leukemia. J Clin Invest 105, 3-7, doi:10.1172/jci9083 (2000). 
294 Zhang, X. et al. Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors. 
International journal of molecular sciences 16, 27313-27326, doi:10.3390/ijms161126020 (2015). 
295 Santini, M. T. & Rainaldi, G. Three-dimensional spheroid model in tumor biology. Pathobiology : 
journal of immunopathology, molecular and cellular biology 67, 148-157, doi:28065 (1999). 
296 Herrmann, R., Fayad, W., Schwarz, S., Berndtsson, M. & Linder, S. Screening for compounds that 
induce apoptosis of cancer cells grown as multicellular spheroids. Journal of biomolecular screening 
13, 1-8, doi:10.1177/1087057107310442 (2008). 
297 Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F. & Ebner, R. The use of 3-D cultures for high-
throughput screening: the multicellular spheroid model. Journal of biomolecular screening 9, 273-
285, doi:10.1177/1087057104265040 (2004). 
298 Mueller-Klieser, W. Three-dimensional cell cultures: from molecular mechanisms to clinical 
applications. The American journal of physiology 273, C1109-1123 (1997). 
299 Bates, R. C., Edwards, N. S. & Yates, J. D. Spheroids and cell survival. Critical reviews in 
oncology/hematology 36, 61-74 (2000). 
300 Fayad, W. et al. Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a 
three-dimensional carcinoma culture model. International journal of cancer 125, 2450-2455, 
doi:10.1002/ijc.24627 (2009). 
 
